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ABSTRACT
Neuronal cytotoxicity observed in Alzheimer’s disease (AD) is linked to the aggregation
of β-amyloid peptide (Aβ) into toxic forms. Increasing evidence points to oligomeric species as
the neurotoxic species compared to fibrils; disruption or inhibition of Aβ self-assembly into
oligomeric or fibrillar forms remains a viable therapeutic strategy to reduce Aβ neurotoxicity.
Amyloid aggregation mitigating peptides (AAMPs) were designed based on the Aβ
“hydrophobic core” Aβ17-20, with Cα,α-disubstituted amino acids (ααAAs) added into this core as
disrupting agents.

The

number, distribution, and side chain functionality of ααAAs

incorporated into the mitigator sequence was found influences the resultant aggregate
morphology as indicated by ex-situ experiments using AFM and TEM. For instance, AAMP-5
incorporating the sterically hindered diisobutyl side chain to its core sequence disrupted fibril
formation. However, AAMP-6 with a dipropyl side chain incorporated into its core sequence
only altered fibril morphology, forming shorter and larger sized fibrils compared to those of Aβ140.

Interestingly, ααAA-AAMPs also disassembled preformed fibrils to produce either

amorphous aggregates or protofibrillar structures, suggesting the existence of equilibrium
between fibrils and prefibrillar structures. Also, AAMPs aged alone did slowly aggregate to
form spherical structures, which is inconsistent with circular dichroism spectra showing an
unchanged random coil structure.
Several potent mitigators of Aβ fibrillization were derived from N- or C- terminus modification
of KLVFF with various polar groups. The number of ααAAs and polar groups were reduced
without

affecting

the

overall

disruptive

x

properties

of

the

original

mitigator.

CHAPTER 1
GOALS, RESEARCH SYNOPSIS, AND BACKGROUND
1.1 Research Goals and Aims
The predominant hypothesis for the causative agents for neuronal toxicity and cell death
observed in Alzheimer’s disease (AD) are oligomeric assemblies.1-8 One therapeutic approach is
to target changes in the Aβ assembly process into toxic forms. The goal of this research involves
the design and synthesis of amyloid aggregation mitigating peptides (AAMPs) that incorporate
ααAAs. The use of ααAAs is of particular interest because they have been shown to induce
extended conformations9 required for model peptides to interact and disrupt the Aβ assembly
process
The specific aim of this research was to investigate the role of specific changes for one or
two ααAAs on the Aβ assembly and disassembly process as compared to the original designs.
The role of polar residues was also investigated with the view of reducing the overall charge of
the peptide. The goals were to identify which structural elements of the AAMPs are essential for
disruption of Aβ fibrillization process or fibril dissolution.
1.2 Research Synopsis
Model peptides derived only from natural L-α -amino acids often yield an unordered or unstable
secondary structure, which limits their use in potential drug candidates, biological probes, and
functionalized-device molecules.10,

11

Thus, to increase their stability one of the ways is to

replace the α-hydrogen of L-α-amino acid with an alkyl substituent, which results in ααAAs.
ααAAs are known to induce extended peptide conformations, which are ideal for design
peptides that will interact with Aβ and disrupt its assembly process. The first aim was to

1

improve the yields of ααAAs through modification of the existing routes or development of new
synthetic routes. This will enable us to carry out a large-scale synthesis of ααAAs because large
quantities are required for synthesis of peptide mitigators. Coupling of Fmoc-ααAA-OH onto
N-terminal resin and their N-terminal acylation were found to be difficult.

Thus, various

coupling conditions and methods were evaluated after which a library of ααAA-containing
AAMPs was synthesized.
Mitigators containing ααAAs was previously shown to disrupt Aβ fibrillilization forming
nonfibrillic assemblies that were stable after 4.5 months. In Chapter 3 we show that the number
and position of ααAAs in the recognition element of the original mitigator AAMP-1 (AMY-1)12
is important in determining the effectiveness of the interaction of our AAMPs with Aβ. Also, we
further examine the aggregate inhibition role of each ααAA in AAMP-1 by examination of
synthetically derived AAMP-1 analogs having ααAAs replaced by their natural amino acid
analog (Leu for Dibg, etc). Furthermore, a major finding is that AAMPs that disrupted fibril
formation also led to disassembly of preformed (existing) Aβ1–40 fibrils.
Also our two AAMPs (previously denoted as AMY-1 and AMY-2 and having a
hydrophilic Lys tail on the C- or N-termini, respectively) mitigated Aβ1–40 fibril formation in a
way such that ill-defined Aβ1–40 aggregates of different size were produced. Thus, in chapter 4
we investigate the effect of modifications of the KLVFF hydrophobic core of Aβ by replacing Nand C- terminal groups with various polar moieties. Several of these terminal modifications
were found to disrupt the formation of amyloid fibrils, and in some cases induced disassembly of
pre-formed fibrils. Significantly, mitigators that incorporate MiniPEG polar groups were found
to be effective against Aβ1-40 fibrilligonesis. In addition, we further disclose that the number of
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polar residues (six) and ααAAs (three) in the original mitigator can be reduced without
dramatically changing the ability to disrupt Aβ1-40 fibrillization in vitro.
1.3 Background
1.3.1 Protein Folding and the Evolution of Diseases
Protein folding is crucial for sustaining cellular functions.13, 14 Amino acid sequence, mutations
and environmental conditions such as temperature, oxidative agents and pH determine whether
proteins misfold. When proteins fail to fold, they are degraded by proteasome yielding unfolded
nonfunctional proteins (non-native protein).

The unfolded proteins are thermodynamically

unstable and tend to aggregate to regain stability. The protein aggregates formed are deposited
either in the body system or on organs leading to amyloidosis diseases (Table 1.1).
Table 1.1. Examples of protein misfolding diseases.
Disease

Precursor protein

Deposition location

Alzheimer’s disease

β-Amyloid, Tau

Brain

Parkinson’s disease

α-synuclein

Brain

Huntington’s disease

Huntington

Brain

Creutzfeldt-Jakob disease (mad cow) Prion protein

Brain

Amyotrophic lateral sclerosis

Superoxide dismutase

Brain

Diabetes mellitus

Amylin, IAPP

Pancreas

Atherosclerosis

Lipoprotein

Arteries

Sickle cell anemia

Hemoglobin

Erythrocytes

Renal amyloidosis

Fibrinogen

Kidney

Cataract

Crystalinm

Eye

Senile systemic amyloidosis

Transthyretin

Microvasculature

Injection-localized amyloidosis

Insulin

Skin, muscles
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Deposits localized in the regions of the brain, including the central nervous system, have
been linked to a number of neurogenerative diseases that cause dementia. Alzheimer’s disease
(AD), Prion diseases, Huntington’s disease, and Parkinson’s disease,14-17 are all linked to a
particular protein (Table 1). The most prevalent and most studied neurodegenerative disease is
AD.
1.3.2 Alzheimer’s Disease
1.3.2.1 Historical Background
Alzheimer’s disease is the most prevalent cause of dementia in elderly humans worldwide. The
disease is named after the German neurologist, Alois Alzheimer (1864–1915)18-20 who studied a
51-year-old woman who had developed memory, language and behavioral problems from 19011906. Upon her death, he examined her brain during autopsy, and noted unusual thick bundles
of nerve fibers and the destruction of nerve cells. He concluded that the changes that occurred in
her brain indicated a new disease.21 It was not until 1910 when the disease was named after the
German neurologist. The symptoms Alois Alzheimer described are still being diagnosed in most
patients with the disease today.22
1.3.2.2 Alzheimer Disease Prevalence
Alzheimer’s disease is a permanent, progressive neurodegenerative disease that gradually
decimates memory and cognitive functions.

It is the most common cause of dementia,

accounting for more than half of all such cases, and the sixth leading cause of death in the United
States. This year approximately 5.3 million people in the US have AD disease, out of which 5.1
million people are over 65 years in age.23 New cases of the disease are expected to double by the
year 2050. The health care costs associated with the disease have tripled to more than $148
billion per year, stretching Medicare and Medicaid programs.23 Worldwide, AD affects more
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than 24 million people, with 4.6 million new cases each year. The major risk factor for AD is
age, with the disease prevalence increasing from 1 in 10 people for those over age of 65 to
almost half of those over 85.24
1.3.2.3 Etiology of AD Disease; β -Amyloid Hypothesis
Amyloid deposits which consist of neurofibrillar tangles and senile plaques characterize
the development of AD in the brain.25 A Large body of evidence associates the density of senile
plaques with the severity of dementia.25,

26

Also, there is significant evidence that shows

involvement of Tau protein, the major component of neurofibrillar tangles in etiology of AD.
The principal component of these plaques is β−amyloid peptide (Aβ), which is derived from
proteolytic cleavage of the transmembrane protein, amyloid precursor protein (APP), by β-and γsecretases. Apart from playing a central role as a precursor to Aβ, APP have a number of
additional functions such as autocrine and paracrine functions in growth regulation, neurite
growth stimulation, stem cell regulation, and promotion of cell adhesion. Mounting evidence
implies that perturbation of some of these functions may play a part in the etiology of AD.27-30
Cleavage of APP can occur at three different sites by α, β, or γ secretases as shown in Figure
1.1. The larger extracellular segment of APP peptide is cleaved first by β- or α-secretase,
producing membrane bound β- or α- C-terminal fragments. Subsequent cleavage of the β- and
α-C-terminal fragments within the membrane by γ-secretase releases Aβ and p3 peptides
respectively into the extracellular domain. Two isoforms of Aβ are often produced depending on
γ-secretase cleavage site; Aβ1-40 (between 40 and 41) and Aβ1-42 (between 42 and 43). The other
by-product of γ-cleavage is the cytoplasmic polypeptide, AICD that so far has not been
investigated for any role in the etiology of AD.

5

Figure 1.1.. Cleavage of APP molecule by aspartyl proteases
It is widely accepted that A
Aβ plays a central role in the etiology of AD,
A although the
mechanism of neurotoxicity has not been fully established.13, 20, 31-33 Several human, transgenic
animal, and in vitro studies have supported the central role of A
Aβ in etiology of AD.
AD For
instance, synthetic Aβ has been shown to be toxic to neurons both in vivo34 and in vitro
experiments.35-38 Also, there was an increase in tau hyper
hyperphosphorylation
phosphorylation when transgenic mice
were injected with synthetic Aβ,
β, leading to formation of tangles.39, 40 Monomeric Aβ
A is nontoxic
until it aggregates to form an array of oligomeric and fibrillar structures. Therefore identifying
and characterizing the toxic Aβ
β species is crucial so that compounds that target them can be
developed.
6

1.3.2.4 Aβ
β Αggregation
Α
The peptide Aβ is a normal, soluble component of human plasma and cerebrospinal
fluid.41, 42 It is toxic only after it undergoes aggregation and/or conformation change to higher
ordered species such as oligomers or fibrils.35, 43-45 The most common isoforms of Aβ are Aβ40
and Aβ42, which differ only by the length of the C terminus. The concentration of secreted
Aβ42 is about 10% that of Aβ40, and yet the predominant component of senile plaques is
Aβ42.46-49 Biochemical studies have shown that Aβ42 aggregates and forms fibrils more quickly
than Aβ40.50-52 Monomers, dimers, trimers, and tetramers, in rapid equilibrium are the major
early aggregation products of Aβ40.3, 5, 53 In contrast, Aβ42 preferentially form pentamer and
hexamer units (paranuclei) that assemble further to form beaded superstructures, similar to early
protofibrils.54 This could explain why assemblies formed by Aβ42 are more toxic as compared
to those formed by Aβ40 during early stages of oligomerization. Also, over expression of the
two isoforms in transgenic mice demonstrated that Aβ42 is involved in amyloid pathology.55
In vitro, synthetic Aβ has been shown to aggregate via various intermediate species
including soluble oligomers, protofibrils, and insoluble fibrils.56 This process depends on a
number of aggregation conditions, such as acidic pH, metal ions, osmolytes, and interaction with
lipid membranes.57-61 The mechanism of Aβ aggregation into the toxic species has been shown
to proceed via two distinct pathways. In the presence of preformed fibrils or plaques, Aβ
aggregates by consecutive association onto the ends of existing fibrils.62,

63

However, in the

absence of seeding, Aβ monomers aggregate into fibrils by a two step-polymerization process;
nucleation and elongation, in which nucleation is the rate determining step.7,

43, 64-66

The

nucleation phase is a result of an energy barrier that must be overcome in order for Aβ monomers
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to fold into nuclei.67 Once the nuclei have been generated, rapid elongation of fibrils occurs in
the linear phase.

Figure 1.2. The nucleation process of fibrillogenesis
fibrillogenesis.
Computer simulation experiments have also shown that monomeric Aβ peptides undergo a twotwo
step process that is reliant on the degree of hydrophobicity
hydrophobicity. In the first step, due to strong
interactions between hydrophobic residues monomers coalesce quickly into disordered
disord
oligomers.

The disordered assemblies reorganize (conformational change) slowly through

formation of interchain hydrogen bonds into ordered oligomers rich in β-sheets
sheets. Because of
conformational change, the hydrophobic residues buried inside the oligo
oligomers
mers are exposed to
interaction with cellular components such as membranes. This could explain the toxic nature of
oligomers. When hydrophobicity is inadequate to drive coalescence to disordered oligomers,
peptides form ordered oligomers directly as a re
result
sult interchain of hydrogen bonds. Temperature
and concentration are other factors that affect formation of disordered assemblies.
8

The morphology of amyloid fibrils formed by various amyloidal proteins such as Aβ, αsynuclei, amylin, and β-microglobulin has been studied using atomic force microscopy (AFM).66
A hierarchical assembly model (HAM) has been proposed to describe the assembly process of
amyloid proteins into fibrils.68, 69 The HAM model predicts that a monomeric amyloid protein
aggregates via a nucleated polymerization mechanism into protofilaments, which elongate by
addition of monomers at the ends of protofilaments. Two or three protofilaments can associate
to form protofibrils that intertwine to form fibrils. In general, the HAM model predicts that
fibrils and protofibrils will exhibit clumping, periodicity, variations in height, and branching.
1.3.2.5 Neurotoxicity of Aβ
β
The original “amyloid cascade” hypothesis linked the deposition of fibrillar Aβ in the
brain to neuronal cell death.

1, 70-72

However, some key observations including poor correlation

between deposition of plaques and severity of dementia contradicts this hypothesis. Therefore,
the amyloid cascade hypothesis was amended to include soluble oligomeric assemblies rather
than fibrils as the main neurotoxic species. This was because a number of studies have shown a
stronger correlation between soluble oligomers and severity of AD than fibrils. In addition,
transgenic mice APP models exhibited memory and synaptic dysfunction long before plaques
(fibrils) were detected.73-75
The solubility and small sizes of oligomeric species is believed to be a crucial factor as to
why oligomers are more toxic than fibrils. In addition, the higher surface area to volume ratio
exhibited by oligomers as compared to fibrils ensures maximum interaction with neurons, hence
increased neurotoxicity. The interaction between oligomers and neurons has been shown to
occur by either insertion of oligomers between membrane layers to generate cytotoxic pores, or
binding of oligomers specifically to neuron surfaces as ligands.76, 77
9

Oligomeric assemblies consist of curvilinear structures (protofibrils) that normally appear
as beaded strings and globular particles with heights ranging from 2-5 nm. Protofibrils were
identified several years ago as intermediates that form during the Aβ assembly process into
fibrils,37,

78

and protofibrils have been shown to kill neurons.1,

79

More recently, globular

oligomers were renamed amyloid–β-derived diffusible ligands (ADDLs) to emphasize their
globular nature but also to differentiate from the general “oligomers” that include nontoxic
assemblies. The ADDLs were initially discovered from aging Aβ1-42 in the presence of clusterin
when no fibrils were formed and yet a dramatic increase in toxicity was observed.6,

80

Only

nanomolar concentrations of Aβ1-42 are needed to make stable ADDLs that have units ranging
from trimers to 24-mers. The hypothesis that ADDLs plays a crucial role in AD is gaining
momentum. This is specifically because ADDLs bind neuronal receptors inducing synaptic
dysfunction rather than the neuronal death caused by fibrils and plaques.

Other general

consequences caused by Aβ aggregates include alteration of the physiological properties of
membranes, membrane-mediated triggering of neuronal cell death, lipid peroxidation, and
calcium-permeable membrane ion-channels. Although increasing evidence points to oligomeric
species as the more toxic species, a general strategy to prevent AD may be to interrupt the
assembly of Aβ into these toxic forms.
1.3.2.6 Strategies for Designing Molecules That Target Aβ
β
Considerable research effort has focused on discovery of inhibitor compounds that block
the toxicity of Aβ, by targeting a specific step involved in Aβ aggregation.81-83 Given the
hypothesis that aggregation intermediates are responsible for Aβ toxicity, such compounds could
theoretically prevent all aggregation, or alternatively cause further association of toxic oligomers
into larger nontoxic aggregates.
10

Several approaches are under development against production of Aβ and related
aggregates. These include inhibition of proteases involved in cleavage of Aβ from APP,8488

antibody therapy through passive immunizations using anti-Aβ antibodies,89-92 non-antibody

based natural mechanism,93-95 small molecules,96-100 and peptides.100

Peptide-based Aβ

interacting molecules are the focus of this dissertation. Interest in peptides has intensified
because they are generally more potent, and show higher specificity and fewer toxicology
problems than smaller molecules. Peptide-based drugs approved by the FDA include natural
peptides, such as insulin, vancomycin, oxytocin, and cyclosporine and synthetically produced
ones, such as Fuzeon (enfuvirtide) and Integrilin (eptifibatide). The development of new nonoral drug delivery methods such as subcutaneous and intranasal implants has increased the
interest in peptide-based drugs.
One approach is to exploit the self-recognition features of Aβ to generate compounds that
can interact specifically with Aβ.101, 102 Tjenberg et al. identified residues 16-20 (KLVFF) to be
essential for fibril formation.62,

103

Pentapeptide KLVFF was also found to be the minimum

sequence required to bind Aβ40/42.102, 104 Several groups have developed amyloid aggregation
mitigating peptides (AAMPs) based on the KLVFF motif that alter aggregation kinetics or
aggregate morphologies of Aβ. The common design of these AAMPs is to use the KLVFF core
as a recognition element, since the initial assembly of Aβ into oligomeric assemblies is
controlled by hydrophobic interactions through side chains.

Several modifications of the

KLVFF motif reported include amino acid substitutions with regular amino acids, α-carbon
modification of some amino acid residues, KLVFF terminal modification using polar groups,
peptide backbone atoms modification with ester, isostructural double bond, N-methylation,
peptide cyclization with cystines, and insertion of D-amino acids.105-107 The design strategy
11

employed both α-carbon and C- or N-terminal modifications to yield AAMPs that we show to be
potent mitigators of Aβ fibrillization.12
1.3.2.7 Structures of Aβ
β Assemblies
ssemblies

Figure 1.3. Structural model of the protofilament in A
Aβ1-140 fibril derived
ved from Tycko et al.
al
Quarterly Reviews of Biophysics 2006, 39, (1), 1-55.
Recent experiments have identified different types of A
Aβ oligomers that include SDS
stable dimers and trimers, protofibrils, annular assemblies, amylospheroids, Aβ-derived
A
diffusible ligands, and Aβ*56,
*56, all of which ha
have different sizes and morphologies.40 This
suggests that several oligomeric species may be involved in the Aβ fibrilization process and
neurotoxicity. The structural characterization of oligomers has not been reported because of
their noncrystaline nature.

Unlike oligomers, fibrils have a well
well-defined
defined structure.
structure
12

Tycko

through solid-state NMR studies has shown that Aβ fibrils favor C2 symmetry.108,

109

The

symmetry is stabilized by hydrophobic interactions between the two parallel sheets adopted by
single Aβ molecules and between two separate Aβ molecules. A salt bridge between Asp23 and
Lys28 also contributes to the stability of the fibril structure.110 Fibrils formed by longer forms of
Aβ (Aβ1-40 and Aβ10-35) were more likely to consist of parallel β-sheets as compared to
antiparallel β-sheets for fibrils formed by shorter peptide segments, Aβ16-22, Aβ11-25, and Aβ34110
42.

1.4 Conclusion
Alzheimer’s disease AD is a neurodegenerative disease that affects nearly 5.3 million people in
the US and new cases of the disease are expected to double by the year 2050. There is still no
cure for the disease, but drugs in the market act only to slow down progression of the disease.
Current approaches to the development of possible therapeutic involve targeting of secretases
responsible for secretion of Aβ as well as the toxic structures formed during Aβ assembly into
fibrils. Oligomeric and protofibrillar assemblies have been shown to be more toxic to neurons
than fibrils.

Unlike fibrils, no structural data has been reported for oligomeric structures.

Structural determination of oligomers is urgently needed in order to find ways of stabilizing or
disrupting their formation. Peptide-based drugs offer great potential because of their specificity
and limited side effects as compared to small molecules, especially with the development of nonoral methods of drug delivery. The lethality of AD and the excessive financial and social cost
associated with it require that all possible leads be pursued.
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CHAPTER 2
SYNTHESIS OF ALPHA, ALPHA-DISUBSTITUTED AMINO ACIDS (αα
ααAAS)
AND
αα
THEN INCORPORATION INTO SHORT PEPTIDES
2.1 Introduction
Peptide-protein or protein-protein interactions play an important role in many cellular processes,
hence what is an increasingly popular source for the design of inhibitors. One approach involves
designing short model inhibitor peptides that will interact with specific residues in the target
molecule.1 Such model peptides allow elucidation of the roles of the target molecules in cellular
function as potential targets for development of new therapeutic agents.

Tjernberg et al.

identified residues KLVFF as critical for self recognition and fibril formation.1 Effective
mitigators of Aβ assembly are reported to incorporate this region in their core sequence. For a
mitigator to interact with Aβ, it has to adopt an extended conformation similar to Aβ. Cα,αdisubstituted glycine residues (ααAAs) have been shown to promote helical or extended
conformation depending on substituent’s at the α-carbon. Thus, short peptides incorporating one
or more ααAAs adopt an extended conformation with two faces where one face containing
ααAAs blocks the necessary hydrogen bonds required for β-sheet extension and the other face is
available for interaction with Aβ.

In addition, ααAAs increase the stability of ααAAs-

containing peptides from proteolytic degradation, enhancing their potential as therapeutic agents.
This dissertation will focus mainly on synthesis of the ααAAs dibenzylglycine (Dbg),
dipropylglycine (Dpg) and diisobutylglycine (Dibg) and their incorporation into model peptides
as possible mitigators of Aβ assembly. We hypothesize that these ααAAs that have larger side
chains than methyl groups when incorporated into a model peptide will induce extended peptide
conformations.

Thus, peptides containing ααAAs would have strong affinity for β-sheet

assemblies and block one punative face from hydrogen bonding with another β-sheet moiety.
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The inhibitor peptides consist of hydrophobic core of Aβ16-20 where ααAAs are substituted
into hydrophobic core of Aβ at key positions.
2.2 Experimental Section
2.2.1. Materials and Instruments
2.2.1.1 Materials
Fmoc-protected amino acids and Fmoc-PAL-PEG-PS support (initial loading 0.16-0.22
mmol/g) were purchased from Applied Biosytems (Foster, CA), Novabiochem (Darmstadt,
Germany), or Peptide international (Louisville, KE). N-[(dimethyamino)-1H-1, 2, 3-triazolo[4,
5-b]pyridino-1-ylmethylene]-N-methylmethanaminium hexafluorophosphate N-oxide (HATU),
7-azabenzotriazol-1-yloxy-tris-(pyrrolidino) phosphonium hexafluorophosphate (PyAOP), Nhydroxybenzotriazole (HOBt),

1-Hydroxy-7-Azabenzotriazole (HOAt), O-Benzotriazole-

N,N,N’,N’-tetramethyl-uronium-hexafluoro-phosphate (HBTU), and

O-(Benzotriazol-1-yl)-

N,N,N',N'-tetramethyluronium tetrafluoroborate were obtained from Applied Biosystems (Foster
CA) or GL Biochem Ltd (Shanghai, China). N,N'-dicyclohexylcarbodiimide (DCC), N,N'diisopropylcarbodiimide

(DIC),

bis(2-oxo-3-oxazolidinyl)phosphonic

chloride

(BOP-Cl),

triisopropylsilane (TIPS), trifluoroacetic acis (TFA), benzyl bromide, ethylnitroacetate,
Diisopropylethylamine (redistilled), liquefied phenol and solvents (drum) were purchased from
Sigma-Aldrich

(Milwaukee,

WI).

Diisopropylethylamine

(DIEA),

piperidine

(4-

methypiperidine) and collidine were obtained from Fisher Scientific. TLC plates and silica gel
were purchased from sorbent technologies
2.2.1.2 Instruments
•

GC/MS: Varian Saturn 2200 GC/MS
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•

Mass Spectrometry: Bruker ProFLEX III MALDI-TOF mass spectrometer and Agilent
6210 time-of-flight MS

•

2.2.1.2.3 Microwave: MARS System with XP-1500 PlusT vessels, the ESP-1500 Plus
and RTP-300

Table 2.1 microwave-coupling conditions
Amino acid

Power (watts)

Coupling time

Hold temperature

ααAAs

400

10

95

Symmetrical anhydride

400

20

75

Natural amino acid

400

5

75

•

Peptide Synthesizer: MilliGen 9050 PepSynthesizer

•

NMR: Bruker DPX-250 and Bruker AV-400

•

Amino Acid Analysis: Dionex AAA-Direct instrumentation

•

Circular dichroism (CD): Aviv Circular Dicroism Spectrometer Model 62DS

•

HPLC: Waters
Software:

Empower

Controller:

Waters 600E (multisolvent delivery system)

Pump:

Waters 625

Detector:

Waters 486 UV detector set at 220 nm

Columns:

Waters Delta-Pak C4 (15µm, 100 Å), 8×100 mm for analytical HPLC
Waters Delta-Pak C4 (15µm, 100 Å), 25×10 mm for preparative HPLC

Buffer A:

H2O, 0.1 % TFA (v/v)

Buffer B:

ACN, 0.1 % TFA (v/v
25

Table 2.2. Standard method for analytical HPLC
Time (min)
Buffer A (%)
Buffer B (%)
0
90
10
60
30
70
65
30
70
70
90
10
Table 2.3 Standard method for preparative HPLC
Time (min)
Buffer A (%)
Buffer B (%)
0
90
10
60
60
40
65
30
70
70
30
70
75
90
10

Flow (ml/min)
1
1
1
1

UV (nm)
220 nm

Flow (ml/min)
10
10
10
10
10

UV (nm)

220 nm

2.2.2 Synthesis of ααAAs
αα
Facile synthetic routes for ααAAs are required to obtain enough amino acid for solid
phase peptide synthesis of designed inhibitor peptides. Syntheses followed previously published
procedures with some slight modifications. Fmoc reactions were carried out following Bolin
procedure.2
2.2.2.1 Synthesis of Nα− Protected Dipropylglycine(Dpg)
2.2.2.1.1 5, 5-Dipropylhydantoin (1a)
Previously synthesized following bucherer-Bergs protocol for aldehydes or ketones.3, 4 A
solution of 4-heptanone (20 g, 175.2 mmol), potassium cyanide (24 g, 367.6 mmol), and
ammonium carbonate (37.2 g, 385.2 mmol) in methanol (100 mL) and water (100 mL) was
heated at 50 ºC in a capped vessel for 36 h. The precipitated solid was filtered and washed with a
+small portion of water and dried in air to yield the hydantoinhydantoin 1a as an off-white
powder (25.0 g, 80% yield). 1HNMR (250 MHz, CD3SOCD3) δ: 10.55 (s, 1H), 7.81 (s, 1H),
1.69 -1.57 (m, 4H), 1.43 -1.38 (m, 2H), 1.22 -1.19 (m, 2H), 0.88 - 0.85 (t, 6H).
MHz, DMSO-d6) δ: 178.89, 157.71, 76.07, 66.49, 17.11, 14.77.
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13

C NMR (75

2.2.2.1.2 2, 2-Dipropylglycine (2a)
The hydantoin 1a (18 g, 97.8 mmol) was suspended in 5 N NaOH (272 mL, 1.36 mol),
and refluxed for 40 h. The mixture was then cooled and acidified to pH 6.5 with concentrated
HCL. The precipitate that formed was then filtered, concentrated in vacuo, and further washed
with a small portion of acetone to remove the unreacted hydantoin. Both the filtrate residue and
the solid that precipitated out upon acidification were extracted with warm ethanol several times.
Dipropylglycine (Dpg) was obtained as a white solid upon removal of ethanol in vacuo. The free
amino acid 2a was purified using Dowex 50X8-400 ion exchange resin, packed tightly in a
büchner funnel connected to suction pressure. The resin was activated by rinsing with 2N HCl
and then with water until the eluent was neutral. Dipropylglycine was dissolved in 2 N HCl,
added to the activated resin, and rinsed with water (3 L) to remove all inorganic salts that were
formed during acidification. The amino acid bound to the resin was washed off the resin with 2
N NH4OH (2 L) and solvent removed in vacuo to yield 2a (15.6 g, 75%). Anal. Calcd. for
C10H21NO2: C, 60.35; H, 10.76; N, 8.80; Found: C, 60.14; N, 10.73; N, 8.73.

1

HNMR (250

MHz, CD3SOCD3) δ: 7.34(s, 2H), 1.51-1.10 (m, 8H), 0.87-0.78 (t, 6H).
2.2.2.1.3 9-Fluorenylmethoxycarbonyl-2, 2-dipropylglycine (3a)
Trimethylsilylchloride (7.27 mL, 57.26 mmol) was added in one portion to a suspension
of 2a (4.52 g, 28.63 mmol) in 45 mL of anhydrous CH2CL2, and refluxed for 8 h. The mixture
was cooled in an ice bath then, N, N-diisopropylethylamine (9.85 mL, 57.26 mmol) and Fmoc
chloride (6.73 g, 26.02 mmol) were added. The solution was stirred at 0˚C for 30 min before the
reaction was allowed to warm up to room temperature and stirred further for 24 h. The resulting
mixture was concentrated in vacuo to provide an oil that was dissolved in DI water (60 mL),
acidified to pH 2 with 12 N HCl, and then extracted with ethyl acetate (3×60 mL). The
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combined organic layers were dried over anhydrous MgSO4 and concentrated in vacuo to
provide a yellow solid which was triturated in hexanes to afford a white solid product 3a (8.51
g, 86%). 1HNMR (250 MHz, CD3SOCD3) δ: 10.68 (s, 1H), 7.91-7.88 (d, 2H), 7.71 - 7.69 (d,
2H), 7.44-7.29 (m, 4H), 6.95 (s, 1H), 4.28 - 4.21 (m, 3H), 1.76 - 1.74 (m, 4H), 1.20 - 1.10 (m,
2H), 0.86 - 0.82 (m, 6H). Anal. Calcd. for C25H31NO4: C, 74.42; H, 7.13; N, 3.67. Found: C,
72.57; H, 7.30; N, 3.80.
2.2.2.2 Synthesis of Nα-Protected Dibenzylglycine
Dibenzylglycine was

synthesized following previously reported protocol

from ethyl nitro

acetate.3
2.2.2.2.1 Ethyl 2-benzyl-2-nitro-3-phenylpropanoate (1b)
To a solution of ethyl nitroacetate (1.0 g, 7.51 mmol) in dry DMF (5 mL) was added
DIEA (2.0 g, 15.4 mmol) and Bu4N+Br– (0.24 g, 0.75 mmol). To this clear yellow solution,
benzyl bromide (2.6 g, 15.4 mmol) was added and the reaction spontaneously warmed to 60 ºC
over 5 min. After 20 min., DIEA•HBr precipitated out of solution. After 1 h, DIEA•HBr was
filtered, washed with ether (100 mL), and the combined filtrate washed with H2O (5 x 50 mL).
The organic layer was dried (Na2SO4) and ether removed under vacuo to provide a yellow oil,
which was of sufficient purity to be used in further reactions or could be purified by silica gel
chromatography using pentane : ether (90:10) to provide a white solid 1b, yield 0.55 g (55%).
2.2.2.2.2 Ethyl 2, 2-dibenzylglycine ester (2b)
To a solution of nitro ester 1b (0.51 g, 1.80 mmol) in glacial AcOH (1mL) and absolute
ethanol (10 mL), a catalytic amount of Raney Nickey 50 % (w/v) was added. The resulting
mixture was reduced over hydrogen gas; pressure (50 psi) for 24 h. Raney Nickel was filtered
over Celite cake and washed with 30 mL of ethanol. Ethanol was removed in vacuo and the
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crude product dissolved in 30 mL diethyl ether, washed with 10 mL (3X) saturated sodium
carbonate, and then with 10 mL (3X) brine. The resulting organic fraction was dried over
anhydrous sodium sulfate for 45 min and ether removed under vacuo to give the crude product
(0.32 g) which was purified via silica gel column chromatography using ethyl acetate: hexane
(70:30).
2.2.2.2.3 2, 2-Dibenzylglycine (3b)
A suspension of dibenzylglycine ester 2b (0.90 mg, 0.35 mmol) in 2 M KOH (50 mL)
and ethanol (25 mL) was refluxed under argon for 24 h. The resulting mixture was concentrated
to 20 mL in vacuo and acidified to pH 6.5 using 12 N HCl. The white precipitate formed was
filtered, washed with cold water (5 mL), and air dried to provide the free amino acid which was
purified via ion exchange chromatography using cationic exchange Dowex 50X8-400 resin to
afford 3b (430 mg, 1.68 mmol). 1HNMR (250MHZ, CD3OD) σ: 7.26 - 7.3 (10H), 3.45 (d, 2H)
2.87 (d, 2H), 1.27 (s, 2H), Anal. Calcd for C16H17NO2: C, 75.27; H, 6.71; N, 5.48. Found: C,
75.12; H, 6.66; N, 5.59.
2.2.2.2.4 Nα-(9-Fluorenylmethoxycarbonyl)-2, 2-dibenzylglycine (4b)
To a suspension of 3b (430 mg, 1.68 mmol) in dry DCM (6.45 mL) was added Trimethylsilyl
chloride (108.64 mg, 3.36 mmol) and refluxed under argon for 8 h. The mixture was cooled to
0ºC in an ice bath and DIEA (129.25 mg, 1.68 mmol) and Fmoc-Cl (390 mg, 1.51 mmol) were
added. The reaction was allowed to warm to 25 ºC and stirred for 30 h. The resulting mixture
was concentrated in vacuo to provide a yellow solid, which was dissolved in water (30 mL),
acidified to pH 2.0 with 12 N HCl, and extracted with ethyl acetate (3 x 35 mL). The combined
ethyl acetate fractions were dried over anhydrous magnesium sulfate and concentrated in vacuo
to provide a light yellow solid. The crude product was triturated in hexanes to afford a white
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solid 4b in75 % yield. 1HNMR (250MHZ, CDCL3) σ: 7.82-7.12 (m, 18H), 5.51 (s, 1H), 4.50 (d,
J = 7 Hz, 2H), 4.30 (t, J = 7.0Hz, 1H), 3.93 (d, J = 13.6Hz, 2H), 3.25 (d, J = 13.6Hz, 2H).
13

CNMR (75 MHz, CDCL3) σ: 177.49, 155.03, 144.21, 141.74, 136.17, 130.13, 128.86, 128.17,

127.53, 125.60, 124.48, 120.42, 67.08, 66.94, 47.67, and 42.17. Anal.Calcd. for C31H27NO4: C,
77.96; H, 5.70; N, 2.93. Found: C, 78.06; H, 5.63; N 2.47.
2.2.2.3 Synthesis of Nα-Protected Diisobutylglycine
Diisobutylglycine was synthesized following previously reported protocol5
2.2.2.3.1 Ethyl 2, 2 – Bis (2-methylallyl)-2-nitroacetate (1c).
To a solution of ethyl nitro acetate (10.0 g, 75.1 mmol) in dry THF (110 mL) were added
2-methylallyl acetate (18.0 g, 157.1 mmol) and Pd(PPh3)4 (4.5 g, 3.9 mmol). After 15 min, DIEA
(20.1 g, 157.1 mmol) was added, and the reaction stirred under argon for 8 h at 50 °C. The
resulting solution was filtered over Celite while washing with THF (2 ×120 mL). The filtrate was
concentrated, dissolved in 75 mL of EtOAc, and washed with 10% K2CO3 (50 mL). To the
organic layer was added 6 g of PS-PPh3 (1.3 mmol/g) Argonaut resin and the mixture was
shaken for 25 min. The resin was filtered and the filtrate purified via column chromatography
using hexane : EtOAc ( 80:20) to provide a light yellow oil 1c (7.65g, yield 97%). 1H NMR (250
MHz, CDCl3) σ: 4.94 - 4.92 (m, 2H), 4.78 - 4.77 (m, 2H), 4.26 - 4.18 (q, 2H), 3.0-2.99 (m, 4H),
1.69 (m, 6H), 1.29 - 1.23 (t, 3H).
2.2.2.3.2 Ethyl 2, 2-Diisobutylglycine Ester (2c).
To a solution of 1c (17.64g, 72.9 mmol) in absolute ethanol (30 mL) were added glacial
acetic acid (4 mL) and a 50 % (w/w) slurry of Raney nickel in water (6.0 g). The reaction was
hydrogenated over H2 gas (50 psi) for 24 h. The resulting solution was filtered carefully over
Celite while washing with EtOH (2 x 50 mL). The solvent was removed in vacuo and the crude
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dissolved in diethyl ether (80 mL), washed with saturated sodium carbonate (60 mL), and brine
(60 ml). The resulting organic fraction was dried over anhydrous sodium sulfate and reduced
under vacuo to afford 2c (14.2g, 90% yield). 1H NMR (250 MHz, CDCl3) δ: 4.08 - 4.0 (q, 2H),
1.67 -1.59 (m, 6H), 1.40 -1.35 (m, 2H), 1.21-1.16 (t, 3H), 0.85 - 0.82 (m, 6H), 0.73 - 0.71 (m,
6H).
2.2.2.3.3 2, 2-Diisobutylglycine(3c).
A suspension of 2c (14.2 g, 65.7 mmol) in 3 M KOH (200 mL) and ethanol (100 mL)
was refluxed under N2 for 24 h. The resulting mixture was concentrated to 100 mL and acidified
to pH 6.5 with 12 N HCl. The solvent was evaporated and the residue re-dissolved in a minimum
amount of water (~50 mL). The mixture was added to an activated Dowex 50X8-400 ionexchange resin (600 g) washed with 2 L of water and then eluted with methanol (300 mL) and 2
N NH4OH (2 L). The collected 2 N NH4OH fractions were evaporated in vacuo to give the free
amino acid 3c (9.5g, yield 83%) as a white powder. mp 224 - 227 ºC; 1H NMR (250 MHz,
DMSO-d6) δ 7.3 (s, 2H), 1.76-1.70 (m, 2H), 1.62-1.43 (m, 4H), 0.86-0.83 (m, 12 H); 13C NMR
(75 MHz, DMSO-d6) δ: 172.2, 62.7, 45.9, 25.0, 23.3, 23.0; Anal. Calcd. for C10H21NO2: C
64.13; H, 11.30; N, 7.48. Found; C, 64.39; H, 11.84; N 7.60.
2.2.2.3.4 Synthesis of
diisobutylglycine(4c)

Nα-Protected

Dibg.

N-(9-Fluorenylmethoxycarbonyl)-2,

2-

Trimethylsilychloride (8.8 g, 81.0 mmol) was added to a suspension of the amino acid 3c
(7.4 g, 39.6 mmol) in dry CH2Cl2 (80 mL) and refluxed under N2 for 8 h. The mixture was
cooled to 0°C, and DIEA (10.5 g, 81.0 mmol) and Fmoc-Cl (10.0 g, 38.6 mmol) were added. The
reaction was allowed to warm to 25 °C and stirred for 20 h. The resulting mixture was
concentrated in vacuo to provide a yellow solid that was then dissolved in EtOAc (80 mL). To
this mixture, water was added (40 mL), and the solution acidified to pH 2.0 with 2 N HCl. The
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separated organic layer was dried over magnesium sulfate and concentrated in vacuo to provide a
light yellow solid. The crude product was triturated in hexanes to afford a white solid 4c (13.7 g,
88% yield): mp 132-133 °C; 1H NMR (250MHz, DMSO-d6) δ: 7.90-7.28 (m, 8H), 6.48 (s, 1H),
4.33 (d, J ) 6.7 Hz, 2H), 4.20 (t, J ) 6.7 Hz, 1H), 2.03-1.97 (m, 2H), 1.63-1.48 (m, 4H), 0.80-0.76
(m, 12 H);
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C NMR (75 MHz, DMSOd6) δ:175.7, 153.4, 143.7, 140.7, 127.6, 127.0, 125.0,

120.1, 64.9,61.5, 46.7, 43.6, 23.8, 23.7, 23.1. Anal. Calcd for C25H31NO4: C, 73.32; H, 7.63; N,
3.42. Found: C, 73.50; H, 7.76; N 3.52.
2.2.3 Peptide Synthesis.
2.2.3.1 General
All peptides were synthesized by solid phase peptide synthesis (SPSS) on PAL-PEG-PS resin
(0.16-0.22 mmol/g) or Rink amide resin (0.52 mmol/g) either manually or on automated pioneer
peptide synthesizer.
2.2.3.2 Attachment of the First Residue on the Resin.
The resin is swollen in DMF or DCM for 20 min and drained before use. The first amino
acid residue attached to the resin linker is always coupled twice to increase the overall peptide
yield and prevent formation of C-terminally related truncated peptides.
2.2.3.3 Removal of the Fmoc Protective Group
A solution of 5 % piperidine and 2 % DBU in DMF (4 ml/g resin) is added to resin. The mixture
is shaken for 2 min at room temperature and drained. This is repeated for 5 and 10 min before the
resin is washed with DMF (5×1 mL) and DCE (5×1mL).
2.2.3.4 Amino Acid Coupling
Amino acid (4 equiv) and HBTU/HOBt (4 equiv each) is dissolved in 0.5 M DIEA and added to
the unprotected resin (1 equiv) for 1 hr while shaking. The coupling mixture is drained and resin
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washed with DMF (5×1 mL), and DCM (5×1 mL). For difficult couplings especially ααAAs, the
stronger activating agents such as PyAOP/HOAt or HATU/HOAt were used and couplings
carried out using DCE: DMF (2:1) as solvent and at elevated temperature (50°C). Small
quantities of resin are tested for un-reacted amine with bromophenol blue test. If the test is
positive, the coupling reaction is repeated
2.2.3.5 N-acylation of ααAAs
Using Symmetrical Anhydrides.
αα
10.0 equiv of amino acid (relative to resin) is dissolved in dry DCM under argon (drops of DMF
may be needed for complete dissolution) and cooled to 0 °C. 5.0 equiv of DIC (relative to resin)
are slowly added. The mixture is stirred for 30 min before DCM is evaporated and residue
dissolved in a minimum amount of DCE: DMF (9:1). The mixture is added to the resin for 8 hr at
50°C while shaking. Resin is filtered, washed with (5×1 mL), (5×1 mL) and small quantities of
resin are tested for un-reacted amine with bromophenol blue test. If the test is positive, the
coupling reaction is repeated
2.2.3.6 Capping of Unreacted Sites
Resin is capped specifically after difficult couplings using 0.2 M acetic acid and 0.28 M
DIEA (24 mL) for 2 hr to terminate deletion sequences arising from unreacted sites. Capping
solution is removed and resin washed with DMF (10 ×1mL).
2.2.3.7 Peptide Cleavage
Resins

were

treated

with

standard

cleavage

solution

(trifluoroacetic

acid:

triisopropylsilane: water: phenol (8.8:0.2:0.5:0.5) at room temperature for 2 h to cleave the
peptide from the solid support. After filtration, the filtrate is diluted in cold ethyl ether and
allowed to co-precipitate overnight. The precipitate was centrifuged at 40,000 rpm, washed with
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cold ethyl ether, and centrifuged for ten minutes (3x). The supernatant was filtered and the
resulting pellet allowed to dry overnight yielding the crude product.
2.2.3.8 Fmoc Analysis
Coupling yields for each step were determined by detection of Fmoc-piperidine conjugate
using a UV spectrophotometer at 300 nm and the absorbance reading was used to calculate the
yield based on the new resin substitution as compared to the original. Also bromophenol blue
(10% in acetonitrile) was used to monitor the presence of free amine; blue color, positive test
while yellow color is a negative test.
2.2.3.9 Circular Dichroism Measurements
All measurements were carried out using an Aviv Circular Dichroism Spectrometer
Model 62DS with Igor plotting software. The CD spectra are averages of three scans made at
1.00 nm intervals acquired from 250 nm to 190 nm (UV Abs range) recorded at 25 0C.
2.3 Results and Discussion
2.3.1 Synthesis of ααAAs
αα
The ααAAs, Dibg, Dbg, and Dpg are achiral analogues of the natural amino acids
leucine, phenylalanine, and alanine respectively (Scheme 1). The most common method of
synthesizing ααAAs is via Bucherer-Bergs or Strecker syntheses,6 yet only Dpg was
successfully synthesized using this method (Scheme 2). The only modification to this procedure
was the longer reaction time, and improved work up procedures during the Fmoc reaction of 2a
which resulted in dramatic increase in yield of 3a (68%) to 86%. The other amino acids, Dbg,
and Dibg failed because they form sterically hindered hydantoins, which are extremely difficult
to hydrolyze to free amino acids even under extremely harsh conditions.
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Scheme1

This prompted development of other alternative synthetic routes to ααAAs such as glycine anion
and cation equivalents.7 Nitroacetate esters have long been recognized as potentially useful
synthetic intermediates for the preparation of amino acids as well as other biologically
significant compounds.8
Scheme 2

Fu et al, devised a strategy that uses commercially available ethyl nitro acetate, tertiary base, and
a catalyst to synthesize the dialkylated nitro esters such as ethyl 2, 2-dibenzylglycine ester 1b
(Scheme 2). The nitro ester was then reduced to the free amine 2b using hydrogen gas in
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presence of Raney nickel, followed by hydrolysis of the ester using KOH/EtOH to afford the free
amino acid 3b. The N-terminal of 3b was protected with Fmoc protecting group to yield 4b,
which was suitable for SPPS.
Scheme 3

The overall yields were consistent with those reported by Fu (Scheme 3). The only
modification to this method was the workup procedure for extracting 4b from the reaction
mixture. We found that some of the product was washed off during ether washings. To solve
this, the crude product was directly dissolved in water, acidified to pH 2 (if necessary), and
extracted with ethyl acetate to yield Fmoc protected dibenzyl glycine 4b in an improved yield of
75 %. Most of the intermediate synthetic steps were high yielding except the initial dialkylation
of ethyl nitroacetate. The low yields dropped further to 30% when the reaction was scaled up (30
%). The reaction conditions, change of base, and order of addition were optimized in an effort to
improve the yields, and results are presented in Table 2.4. The overall strategy is to have a
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synthetic route that is simple, reproducible, and has the ability to be scaled up in order to
synthesize enough amino acid for peptide synthesis.
Table 2.4. Alkylation of ethyl nitroacetate.
Ester

Bromide

Base

O2NCH2CO2Et
O2NCH2CO2E
O2NCH2CO2E
O2NCH2CO2E

PhCH2Br
PhCH2Br
PhCH2Br
PhCH2Br

DIEA
DIEA
DIEA
DIEA

O2NCH2CO2Et PhCH2Br DIEA
O2NCH2CO2Et PhCH2Br t-BuO-K+

Scale of Ester
(mmoles)
7.51
7.51
7.51
7.51
37.5
7.51

Order
of
addition
Base first
Base first
Base last
Base first
Excess solvent
Base first
Base first

%Yield

Temp° C

50
55
44
57

Room temp
0
Room temp
0

30
52.2

Room temp
Room temp

The yields were slightly improved when the reaction was carried out at 0° C as compared to
room temperature (Table 2.4). Alkylation of ethyl nitroacetate is an exothermic reaction, and
explains why higher yields are observed at 0° C as compared to room temperature. Changing the
order of addition between the base and benzyl bromide showed no significant effect on the yield
of dialkylated product. Further investigations of the extraction procedure, reveals that some of
the product was detected in solvent waste during rotary evaporation, bringing into question the
stability of 1b. This is supported by the improved yields obtained when benzyl bromides having
electron withdrawing groups were used. Microwave irradiation technology has been introduced
to organic synthesis, and in particular has been successfully employed to hydrolyze sterically
hindered hydantoins.4 Thus Dbg, which previously failed because of hydantoin hydrolysis
problems, can now be synthesized via Bucherer-Bergs or Strecker syntheses, the most common
method of synthesizing ααAAs.
Synthesis of Dibg was accomplished via Palladium mediated diallylation of ethyl
nitro acetate to obtain the dialkylated nitro ester 1c in 97% yield (Scheme 4).9 The other
synthetic steps were the same as for Dbg (scheme 3). This synthetic route is facile and efficient
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as depicted by the high yields in all the reaction steps. The only modification to this procedure
was the amount of palladium catalyst used, which was reduced to 1% without affecting the yield
of 1c. This also helps to reduce the amount of polystyrene bound triphenyl phosphine needed to
scavenge the palladium catalyst. This leads to a more facile separation in addition to cost
reduction.
Scheme 4

2.3.2 Peptides Synthesis
Incorporation of ααAAs is a recognized way of inducing secondary structure in peptides.10
Peptides without ααAAs were easily synthesized using HBTU or TBTU/HOBt coupling
chemistry in good yields and purity at room temperature. Peptides incorporating ααΑAs were
coupled using various coupling chemistries. All natural amino acids before any ααAAs were
coupled using HBTU or TBTU/HOBT, but those incorporated after ααAAs were generally
difficult to couple, hence coupled using PyAOP/HOAt activating agent. The less sterically
hindered Dpg has been incorporated into peptides via conventional coupling methods in good
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yields.11 Coupling of Dpg were accomplished using PyAOP/HOAt chemistry at 50° C and were
re-coupled. Incorporation of the more sterically hindered ααAAs such as Dbg and Dibg into
peptides was more problematic. Fu et al9 reported optimal coupling techniques necessary for the
incorporation of sterically hindered Dbg and Dibg into peptide sequences. Coupling of Dbg was
achieved using PyAOP/HOAt chemistry while Dibg was coupled via HATU/HOAt chemistry at
elevated temperature and were re-coupled.
The real difficulty mainly stems from the inefficient acylation of the ααAAs N-termini.
Fu also reported that acylation of the N-terminus of these ααAAs is possible via the symmetrical
anhydride method in the absence of a base.12However, we continue to have a lower coupling
yields for acylation of N-terminus of ααAAs especially Dbg. Design of peptides incorporating
ααAAs, places valine after Dbg, which has an isopropyl side chain that we suspect is responsible
for the lower yields. Lysine was easily coupled to Dibg via symmetrical anhydrides. Lysine has
n-side chain as compared to sterically hindered valine.
The low coupling could be because of poor yields of valine (30 %) as compared to lysine
(60%) symmetrical anhydrides. Coupling yields for each coupling step were determined by
Fmoc analysis using a UV spectrometer at 300 nm. Also, bromophenol blue was used to monitor
any unreacted sites. Blue color is a positive test for presence of free amine and yellow is
negative test. All the reaction conditions, equivalents, solvents, ratios, and bases for coupling of
each amino acid are listed in Table 2.5.

The peptide was cleaved from the resin using

trifluoroacetic acid, precipitated out using cold ether, dried, and analyzed using analytical HPLC
and MALDI-MS or ESI. The various AAMPs were synthesized following a general synthetic
route (Figure 2.1). Peptides without ααAAs were generally synthesized in good yields and
purity as analyzed by analytical HPLC.
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Figure 2.1. General synthetic route for the synthesis of AAMPs
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Table 2.5. General reagents and conditions for coupling of various amino acids to a
peptide sequence
Resin
equiv.

Amino
acid
equiv.

Activator

Activator
equiv.

base

Base
equiv.

Solvent

Time
(min)

Temp
°C

Natural
amino
acids
Dpg,
Dbg
Dbg

1

4

HBTU/HOBt

4.0

DIEA

8.0

DMF

3

25

1

4

PyAOP/HOAt

4.0

DIEA

8.0

DMF

3

50

1

4

PyAOP/HOAt

4.0

DIEA

8.0

8

50

Dibg

1

4

HATU/ HOAt

4.0

DIEA

8.0

8

50

acylation
of
ααAAs

1

2

DCC,
DIC, 1.0
BOP-Cl

No
base

-

DCE:DMF
(2:1)
DCE:DMF
(2:1)
DCE:DMF
(9:1)

8

50

Amino
acid

Peptide AAMP-19 is presented as an example to show clean synthesis for peptides
without ααAAs incorporated in their sequence. The chromatogram for AAMP-19 (Figure 2.2)
shows a single peak with Rt = 26.5 min, and was confirmed by ESI-MS as the expected mass ion
peak (837.1 mass units). Purification and mass spectrometry data for various AAMPs are
presented in Table 2.6.
Synthesis of peptides incorporating ααΑAs amino acids were more challenging. For
example, our first attempt to synthesize AAMP-2 failed as no peaks from analytical HPLC crude
(Figure 2.3A) matched the calculated mass ion peak of 1652 mass units for AAMP-2. The major
peak at Rt = 32.67 corresponded to the peptide (DbgPheDpgK6) with Val, Leu, and Lys deleted.
This shows the difficulty of acylating the C-terminus of ααAAs. One major reason for the failed
synthesis was the low concentration of the coupling reagents (0.08M). The peptide was resynthesized using 0.3M concentrations of coupling reagents. Analytical crude HPLC spectrum
(Figure 2.3B) for the re-synthesized peptide showed a peak at Rt = 36.5 which corresponded
with the expected molecular ion peak of 1652 mass units.
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Figure 2.2. HPLC chromatograms of AAMP-19 [A] Analytical HPLC for pure peptide; [B]
Analytical HPLC for peptide synthesized using microwave irradiation; [C] Analytical HPLC for
peptide synthesized using conventional heating method. HPLC conditions for A: 20-40% B in 30
min, 10-70 % B in 80 min for B and 10-70% B in 60 min.
However, the major peak at Rt = 43.5 matched the molecular ion peak for deletion peptide
detected earlier. Further improvements in coupling conditions such as change of coupling
solvents, coupling reagents, were unsuccessful. The real problem with the coupling arises from
poor acylation of the sterically hindered ααAAs, and especially with valine. Couplings yields
showed were slightly increased when valine was replaced with less sterically hindered alanine as
measured by UV Fmoc analysis. To improve the yields microwave irradiation shown recently to
exponentially increase rate of reactions resulting in higher yields in a short time was employed
for difficult couplings.
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Figure 2.3. HPLC chromatograms
omatograms of AAMP
AAMP-2, [A] Analytical HPLC 1st trial. [B] Analytical
spectrum 2nd trial after coupling steps was optimized. HPLC conditions for 1st trial: 10-70%
10
B in
nd
60 min and 10-50
50 % B in 60 min for 2 trial.
Microwave technology has been used in organic chemistry since early 1980 for various
chemical reactions that require heating.13-17 The first application of microwave technology to
peptide synthesis was reported in 1992.18 Microwave irradiation takes advantage of certain
solvents to convert electromagnetic radiation into heat. Growi
Growing
ng peptide chains during
conventional synthesis have a propensity to aggregate. However, during microwave irradiation,
the peptide chains are in constant random motion breaking up any aggregation. Microwave
heating is increasingly used in peptide synthesi
synthesis because coupling yields are significantly
increased in a shorter time. Microwave heating was applied to coupling of sterically hindered
amino acids and its acylation on the N
N-terminus.
terminus. We found increased yields for Dbg coupling
and Val using microwave irradiation,
rradiation, and various coupling methods were investigated to
optimize efficient synthesis of AAMPs.

Microwave irradiation technology was used to

synthesize AAMPs with ααAAs
AAs incorporated into their sequences.

Synthesis of AAMP-8
AAMP

(KLVDbgFAK6) with Dbg inv
involved
olved coupling the first 8 natural amino acids at room
temperature.
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Table 2.6. MALDI-MS results of inhibitor peptides analogs.
Entry

AAMPs

Sequence

Exact

Observed tR

% Peptide

mass

(M+H)+

(min)

content

1

AAMP-0

KLVFFK6

1419.98

1420.99

20.1

67

2

AAMP-1

KDibgVDbgFDpgK6

1707.21

1708.21

24.6

51

3

AAMP-2

KLVDbgFDpgK6

1651.14

1652.15

23.8

39

4

AAMP-3

KDibgVFFDpgK6

1617.16

1618.16

23.9

50

5

AAMP-4

KDibgVDbgFAK6

1637.13

1638.17

25.6

52

6

AAMP-5

KDibgVFFAK6

1547.08

1548.09

22.9

72

7

AAMP-6

KLVAFDpgK6

1561.10

1562.10

21.9

51

8

AAMP-7

KLVDbgFAK6

1581.06

1582.06

25.4

49

9

AAMP-8

KLDpgFFAK6

1533.06

1535.07

23.1

49

10

AAMP-9

KLVFDpgK6

1414.03

1415.05

19.5

50

11

AAMP-10

DibgVFFAK6

1418.99

1419.99

21.2

49

12

AAMP-11

RGKLVFFGR

1077.66

1078.67

27.1

64

13

AAMP-12

KGKLVFFGK

1021.63

1022.65

24.0

100

14

AAMP-13

EGKLVFFGE

1023.54

1024.54

24.5

61

15

AAMP-14

mPEGGKLVFFGmPEG

1055.56

1056.61

24.1

55

16

AAMP-15

RRRGKLVFFGRRR

1702.06

1703.07

20.6

80

17

AAMP-16

KLVFFGR

864.53

865.54

28.1

62

18

AAMP-17

KLVFFGmPEG

853.51

854.52

30.4

83

19

AAMP-18

KLVFFGK

836.53

837.54

23.9

71

20

AAMP-19

RGKLVFF

864.53

865.54

24.6

48

21

AAMP-20

KLVFFDpgGK

977.64

978.65

26.2

60

22

AAMP-21

KGKDibgVFFGK

1077.71

1079.1

24.

58

23

AAMP-22

KDibgVFFDpgGKKK

1289.88

1290.90

27.2

53

24

AAMP-23

KKKGKLVFFDpgGKKK 1676.12

1677.14

21.0

57

25

AAMP-24

KDibgVFFAGKKK

1120.80

1121.76

27.6

62

26

AAMP-25

KLVFFFDpgGKKK

1233.82

1234.84

23.0

65

27

Aβ16-22m

KL(Me)VF(Me)FA(Me)E

895.84

896.85

22.88

66
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The other amino acids were coupled using microwave heating. Conventional synthesis of
the AAMP-8 was carried out to compare the two methods. Analysis of their analytical spectrums
(Figure 2.4) shows an increase in the peptide peak when microwave heating (Figure 2.4B) was
used (Rt = 34.5) as compared to the conventional heating (Figure 2.4C) method (Rt = 36.5).

Figure 2.4 HPLC chromatograms of AAMP-7. [A] Analytical HPLC for pure peptide; [B]
Analytical HPLC for peptide synthesized using microwave irradiation; [C] Analytical HPLC for
peptide synthesized using conventional heating method. HPLC conditions for A: 20-40% B in 30
min, 10-70 % B in 60 min for B and C.
Coupling of the carboxyl group of ααAAs Dbg to a growing peptide chain and acylation
of the N-terminal ααAAs was previously shown to be difficult in both solution and solid phase
peptide synthesis.5 Various coupling methods were investigated for coupling of Dbg and Val
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during synthesis of AAMP-7 by determining the yields using UV analysis at 300 nm of Fmocdeprotection. The first eight amino acids were coupled via automated peptide synthesis and
coupling of Dbg and Val, which follows, was then studied using the various coupling methods
(Table 2.7).
Table 2.7 Coupling of Dbg and then Val onto Phe-Phe-Ala-(Lys)6 (AAMP-7)
Entry Coupling
Base
Solvent
Time
temp yield
agent
Dbg 1
PyAOP/HOAt DIEA
DMF
20 min
95
90
2
PyAOP/HOAt DIEA
DMF
10 min
95
80
3
PyAOP/HOAt collidine DMF
10 min
95
35
4
PyAOP/HOAt DIEA
DMF:DCE 5 min
110 92
(3:1)
5
HATU/HOAt DIEA
DMF:DCE 5 min
110 72
(3:1)
6
PyAOP/HOAt DIEA
DMF
12 h
50
50
7
PyAOP/HOAt DIEA
DMF
12 h
50
30
8
PyAOP/HOAt DIEA
DMF
12 h
50
50
9
PyAOP/HOAt DIEA
DMF
12 h
50
55
VAl 10
DCC
DMF:DCE 1 h
95
61
11
DCC
DMF:DCE 20 min
95
45
12
BOP-Cl
DIEA
DMF:DCE 20 min
95
35
13
DIC
DMF:DCE 20 min
95
45
14
DCC
DMF:DCE 12 h
50
35
15
DiC
DMF:DCE 12 h
50
40
16
BOP-Cl
DMF:DCE 12 h
50
30

Equiv. Conc.
(M)
5
0.3
5
0.3
5
0.3
5
0.3
5

0.3

5
4
8
5
5
5
5
5
20
20
20

0.3
0.3
0.3
0.4

Higher yields for Dbg and Val coupling were obtained in a short time when microwave
irradiation was used as compared to conventional heating. Coupling of Fmoc-Dbg-OH onto the
N-terminus of the Phe on the resin using PyAOP/HOAt was more effective than HATU/HOAt
(entry 4 and 5). The strength of the base used affected the coupling yields of Dbg where higher
yields were realized when DIEA (entry 2) was used as compared to collidine (entry 3). There
was no significant change in yields with longer coupling time (entry 1 and 2), temperature (entry
1 and 4, and solvent mixture (entry 1 and 4). Higher Dbg coupling yields at room temperature
were observed with increased concentration of coupling agents/amino acid (entry 8 vs 9) or
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equivalents of amino acid (entry 7 vs 8). Acylation of Dbg N-terminus was previously coupled
with higher yields using Fmoc-Val symmetric anhydride as compared to PyAOP or HATU
coupling methods. Higher yields were observed for Val coupled earlier (second) in the peptide
sequence as compared to the lower yields we report for Val coupled later in the synthesis (tenth).
Yields for Val were increased when microwave irradiation (entry 10-13) was used as compared
to conventional heating (entry 14-16). Fmoc-Val-OH symmetrical anhydrides obtained from
DCC (entry 10, 11) or DIC (13) used to acylate Dbg N-terminus gave higher yields as compared
to BOP-Cl (entry 12). Similarly, higher yields for coupling Val using Fmoc-Val symmetrical
anhydrides were observed when microwave irradiation was used as compared to conventional
heating.

Figure 2.5. HPLC chromatograms of AAMP-21. [A] Analytical HPLC for pure peptide; [B]
Analytical HPLC for peptide synthesized using microwave irradiation; [C] Analytical HPLC for
peptide synthesized using conventional heating method. HPLC conditions for A: 20-40% B in
30 min, 10-50 % B in 60 min for B and10-70 % B in 60 min for C.
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Another example to show the success of microwave technology was synthesis of AAMP21 (KDibgVFFGK) containing Dibg.

The HPLC spectrum from peptides synthesized by

conventional synthesis showed two closely related peaks (Figure 2.5C). The peak with Rt = 30.5
matched the expected mass ion peak. The other taller peak Rt = 33.8 corresponded to deletion of
Lys, consistent with the problem in acylating the N-terminus of ααAAs. However, using
microwave irradiation method, the deletion peptide observed in conventional heating
disappeared (Figure 2.5B) and a peak (37.8 min) that corresponded to the expected molecular ion
increased.
2.3.3 Conformational Studies of Migators
Circular dichroism studies of sample of peptides were carried out to determine their aggregation
behavior. The effect of the various AAMPs on Aβ assembly into β-sheet structures will be
discussed later in chapters 3 and 4. The CD spectra for all AAMPs showed a characteristic
random coil structure as shown by a large negative band near 200 nm and small positive band
near 220 nm. There was no transition from random coil to β-sheet observed for all the AAMPs
synthesized with varying concentrations. This suggests that the propensity for the AAMPs to
aggregate is minimal, and that they do not misfiled or unfold at higher concentrations through a
multistep folding process. There was no significant difference observed in the CD signal of
mitigators containing ααAAs (Figures 2.6, 2.7 and 2.11) as compared to those without (Figures
2.8-2.10).

Also, mitigators with different terminal modifications (C-, N- and C-, and N-)

displayed similar CD signals (Figures 2.8-2.10).
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Figure 2.6 Concentration studies of AAMP-5. CD spectra taken in 50 mM PBS (150mm NaCl);
pH 7.4. Molar ellipticity- [θ] units- degcm2dmol-1.

Figure 2.7 Concentration studies of AAMP-6. CD spectra taken in 50 mM PBS (150mm NaCl);
pH 7.4. Molar ellipticity- [θ] units- degcm2dmol-1.
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Figure 2.8 Concentration studies of AAMP-11. CD spectra taken in 50 mM PBS (150mm
NaCl); pH 7.4. Molar ellipticity- [θ] units- degcm2dmol-1.

Figure 2.9 Concentration studies of AAMP-16. CD spectra taken in 50 mM PBS (150mm
NaCl); pH 7.4. Molar ellipticity- [θ] units- degcm2dmol-1.

Figure 2.10 Concentration studies of AAMP-19. CD spectra taken in 50 mM PBS (150mm
NaCl); pH 7.4. Molar ellipticity- [θ] units- degcm2dmol-1.
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Figure 2.11 Concentration studies of AAMP-20. CD spectra taken in 50 mM PBS (150mm
NaCl); pH 7.4. Molar ellipticity- [θ] units- degcm2dmol-1.

2.4 Conclusion
The various synthetic methods for ααAAs were improved by modifying specific steps. We
found that ethyl 2-benzyl-2-nitro-3-phenylpropanoate (1b) was unstable to rotary evaporation,
and the compound was detected in the waste. The focus of future work should be on the
possibility of using microwave irradiation to hydrolyze the sterically hindered hydantoin. Solid
phase peptide synthesis of AAMPs without ααAAs was achieved with high purity. Microwave
technology was successfully used to synthesize AAMPs with ααAAs in higher yields than
conventional methods.

The CD spectral analysis shows that all AAMPs displayed a

characteristic random coil structure that was stable to concentration changes. This is important
for use as mitigators of the Aβ assembly process.
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CHAPTER 3
STRUCTURE-ACTIVITY RELATIONSHIPS IN PEPTIDE MODULATORS OF
AMYLOID β -PROTEIN AGGREGATION
3.1 Introduction
Alzheimer’s disease is a progressive, neurodegenerative disorder characterized by
extracellular plaque deposits and neurofibrillary tangles. The plaque deposits are composed
primarily of the 39-42 amino acids, natively unfolded amyloid β-peptide (Aβ) that is derived
from proteolytic cleavage of the extracellular segment of the transmembrane amyloid precursor
protein (APP).1-3 The normal physiological concentration of Aβ in the brain is less than 10 nM.
However, the critical concentration for Aβ to aggregate in vitro into amylogenic forms is 1-10
µM.4, 5 Several hypotheses as to how Aβ aggregates in the brain below the critical concentration
include concentration of Aβ to several orders of magnitude by membranes or organelles,
lowering of critical concentration by acidic pH or metal ions, and covalent adducts between Aβ
and oxidative metabolites allowing Aβ to aggregate at the nanomolar concentrations.5-7
Conversion of monomeric Aβ peptide into the aggregated products (oligomers,
protofibrils and fibrils) in the brain is believed to be the vital event in AD pathology.8, 9 Fibrils
were previously thought to be the species responsible for neuronal toxicity and cell death
(amyloid cascade). However, growing evidence suggests that much smaller soluble oligomeric
species present in the brain correlates better with severity of AD than plaques (fibrils).2,

10-16

Therefore assembly of Aβ into either oligomeric or fibrillic assemblies remains a rational target
to reduce Aβ neurotoxicity. In addition, fibril dissolution agents could be possible targets for
reducing plaque loads in the brain.
Several approaches aimed at reducing Aβ and its related aggregates in the brain are under
development. This include inhibition of proteases involved in the cleavage of Aβ from the
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amyloid precursor protein (APP),17 antibody therapy through passive immunizations using antiAβ antibodies,18-20 non-antibody based natural mechanism,21-23 small molecules24, and
peptides.24 Interest in peptide-based aggregation mitigators has intensified because peptides are
generally more potent, show higher specificity, and fewer toxicology problems than smaller
organic molecules. A number of peptide-based AAMPs that alter Aβ aggregation kinetics or
aggregate morphologies have been developed. All of these peptide based mitigators exploit the
self-interacting Aβ central hydrophobic core (Aβ16−20) as a recognition element since the
assembly of Aβ oligomers is controlled by initial interaction of hydrophobic side-chains.
Several modifications on the hydrophobic core (Aβ16−20) aimed at designing AAMPs that
enhance the disruption of fibril formation and/or induce fibril disassembly have been reported.9,
25-30

Murphy and Kessling added an oligolysine tail to the Aβ16-20 hydrophobic core that

enhanced Aβ aggregation rates resulting in nontoxic fibrillar species.28-30 More recently, RG-/RG polar groups added to N- and C- terminal proved to be effective inhibitors of fibril formation
and protected SH-SY5Y from Aβ toxicity. Amide backbone modifications of Aβ16-20 core with
N-methyl amino acids,31, 32 ester linkages,31, 33 and isostructural E-olefin bond34, 35 disrupted
fibril formation and induced disassembly of preformed fibrils. Also, Soto and coworkers
designed the peptide LPFFD containing a single proline residue in the Aβ16-20 core which disrupt
fibril formation, disassemble preformed fibrils, and increased cell viability.36 Although these
AAMPs altered the Aβ fibrillization pathway by inducing different Aβ aggregate morphologies,
the processes often required unusually high inhibitor/Aβ molar ratios.
Our design of AAMPs is also based on the Aβ16-20 hydrophobic core where some natural
amino acids were replaced by the modified analogues (ααAAs). The α-carbon of the natural
amino acid was modified by introducing a second similar side chain to form ααAAs. When
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ααAAs are incorporated in short peptides, they are known to induce stable extended
conformations which are ideal for interacting with Aβ through hydrogen bonding as well as by
side-chain interactions. ααAAs are placed at alternating positions (i, i+2, i+4) which positions
them on the same hydrogen bonding face of the extended peptide, sterically blocking it from
further hydrogen bonding hence disrupting fibril propagation. Also, ααAAs with larger side
chains impose restrictions of peptides that contain them. Thus, peptides incorporating ααAAs
could be better disrupters of β-sheets than proline-containing mitigators.36 Peptide mitigators
containing ααAAs with methyl side chains have long been known to disrupt β-sheets.37 Thus,
we hypothesize than mitigators incorporating ααAAs with side chains larger than methyl groups
should be effective disrupters of β-sheets (disassemble preformed fibrils).
We previously communicated that peptides containing ααAAs altered Aβ assembly
pathway at stoichiometric and sub-stoichiometric concentrations resulting in non-fibrillic, nontoxic assemblies.38 The two mitigators (AMY-1 and AMY-2 with hydrophilic Lys tail on C-and
N-terminal respectively) mitigated Aβ1-40 fibril formation producing particles with different
sizes. Herein, we show that the number and position of ααAAs in the recognition element (Aβ
central hydrophobic core) of the original mitigator AAMP-138 is important in determining the
effectiveness of the interaction of the AAMPs with Aβ. Also, we further examine the role of
each ααAAs in AAMP-1 through the synthesis of AAMP-1 analogs where ααAAs were
replaced by their natural amino acid analog (Leu for Dibg, etc). This Aβ1-40-AAMP interaction
nucleates the size and morphology differences of the nanoparticles formed as determined by
AFM and TEM. We also show that AAMPs alone do slowly aggregate forming exclusively
spherical particles. This might provide insight into the mechanism by which they disrupt Aβ1-40

56

fibril formation. A major finding was that mitigators, which disrupted fibril formation, also
disassembled preformed fibrils.
3.2 Materials and Methods
3.2.1 Peptide Synthesis
Samples of AAMPs were prepared from 9H-fluoren-9-ylmethoxycarbonyl (Fmoc) amino acids
using solid phase peptide synthesis (SPSS) on PAL-PEG-PS resin or Rink amide ChemMatrix
resin. Couplings, Fmoc removal, and resin cleavage were carried out using previously described
methods.39-41 The crude peptides were purified by reversed phase HPLC using a 10% to 70% B
linear gradient over 60 min [Waters C4 100 Å column using Solvent A (water and 0.1% TFA)
and solvent B (acetonitrile and 0.1% TFA)]. The purity of the peptides were checked by
analytical HPLC, and the masses confirmed by ESI-MS. The percent peptide content was
established by amino acid analysis. This was discussed in Chapter 2.
3.2.2 Peptide Monomerization
Lyophilized Aβ1-40 (Invitrogen Corporation, Carlsbad, CA, USA.) was pretreated to form
monomeric solutions following our previously published protocol.42

Briefly, Aβ1-40 was

dissolved in neat trifluoroacetic acid (TFA) at 1 mg/mL and sonicated for 10-20 min. Removal
of TFA using a centrivac yielded a dark yellow oil, which was re-dissolved in 1 mL of
hexafluoroisopropanol (HFIP) at 1 mg/mL and incubated at 37 °C for 1 h. Removal of HFIP
yielded a white powder, which was re-dissolved in HFIP and split into 0.25 mg fractions based
on the assumption that the mass of Aβ1-40 was 50 % at this point in the preparation. The
fractions were incubated for 1 h upon which HFIP was removed, and the resulting white powder
was lyophilized overnight. The lyophilized white powder was dissolved in 2 mM NaOH and
PBS (100 mM, 300 mM NaCl, pH 7.4) at 1:1 and centrifuged for 20 min at 13,000 g, which was
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then ready for the aggregation assay. The supernatant was subjected to amino acid analysis to
determine the net peptide content.
3.2.3 Thioflavin T Aggregation Assays
Monomerized Aβ 1-40 was aged alone and in the presence of AAMPs at 37 °C while shaking in
PBS buffer (50 mM, 150 mM NaCl pH 7.4). At various time points, 10 µl of sample, 10 µL of
100µM ThT stock solution in water, and 180 µL of PBS were mixed in a low binding 96 well
plate with clear bottom (Corning or Falcon).

A ThT fluorescence emission spectrum was

acquired at 480 nm (excitation at 440 nm) using a fluorescence plate reader (BMG, LABTECH).
3.2.4 Circular Dichroism
Monomeric samples of Aβ 1-40 were aged alone and with equimolar AAMP at 37 °C for several
days while shaking. The CD spectrum was recorded at room temperature on an Aviv CD
spectrometer.
3.2.5 Atomic Force Microscopy
A sample aliquot of 10 µL was diluted two-fold and adsorbed onto the surface of freshly cleaved
mica (0001) for 5-10 min (Ruby muscovite mica, S&J Trading Co., NY). The remaining excess
liquid was absorbed onto a filter paper or lab tissue. Salts and excess unbound peptide were
removed by rinsing the surface three times with 40 µL of deionized water. An Agilent 5500
atomic force microscope (AFM) equipped with Pico Scan v5.3.3 software was used for surface
characterizations (Agilent Technologies AFM, Inc. Chandler, AZ). Cantilevers (NSL-20) from
Nanoworld Holdings AG (Schaffhausen, Switzerland) were used for imaging samples by tapping
mode in air.

The cantilever was driven to oscillate at 185± 10 kHz for ambient AFM

characterizations.
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3.2.6 Transmission Electron Microscopy
Samples for TEM analysis were prepared by placing sample droplet onto a carbon support Cu
coated grid (EMS 400-CU) for 1-2 min. Excess sample was absorbed into a filter paper, placed
onto a droplet of water, and then stained using 2% uranyl acetate droplet. The grid was cleared
of excess uranyl acetate, labeled, and then stored in a Petri dish. Images were recorded using a
JEOL 100 CX TEM, 80 kV accelerating voltage.
3.3 Results and Discussion
3.3.1 Design of Amyloid Aggregation Mitigating Peptide
The central hydrophobic region of Aβ (16-20) is responsible for self-association and aggregation
leading to the formation of mature fibrils.25 When incorporated into a peptide, ααAAs are
known to induce extended peptide conformations, which are ideal for interaction with Aβ.43, 44
We hypothesize that peptides containing alternating natural amino acids and ααAAs in a βstrand (extended) conformation would have one hydrogen bonding “face” blocked due to the
steric hindrance associated with ααAAs, and the other face would remain accessible for
additional β-strand hydrogen bonds.

This design strategy (Figure 1) does not prevent Aβ

oligomerization but disrupts additional peptides from adding to one face of the growing β-sheet,
thus changing the Aβ fibrilization pathway. Previously, we have shown that no fibrils were
observed from AAMP-1/Aβ1-40 mixture after 4.5 months of incubation at room temperature.38 In
this study, we seek to elucidate the relationship between size and morphology of the resulting
assemblies with the side chain functionality, as well as the positioning and distribution of
ααAAs in the recognition element (KLVFFA) of AAMPs. A library of AAMP-1 analogs was
synthesized and evaluated for ability to disrupt Aβ1-40 fibril formation (Figure 3.1). Mitigator
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AAMP-0 (KLVFFK6) previously described by Murphy and coworkers was used as control
peptide due to the similarity in design strategy to our AAMPS but with no ααAAs .28, 29

Figure 3.1. Design of mitigators with ααAAs as disrupters of Aβ assembly.
When bound to amyloid fibrils Thioflavin T dye (ThT) undergoes a red shift of its
absorbance maximum from 342 to 442 nm, resulting in a characteristic enhanced fluorescence
signal at 482 nm. Binding of the ThT dye to Aβ fibrils is complete within 1 min and does not
interfere with Aβ aggregation.

Thus, ThT fluorescence is commonly used to monitor the

presence of Aβ fibrils and their rates of formation. It has also been shown that ThT can bind to
certain amorphous aggregates to produce an increased fluorescence signal.45-47 Therefore, ThT
fluorescence cannot be used solely to monitor Aβ formation or disruption. Other complementary
methods such as circular dichroism (CD), AFM, and TEM, which reveals the conformation, size,
length, and morphology of aggregates, are needed to probe mitigation of Aβ1-40 fibril formation
by designed inhibitors. We shall emphasize high-resolution AFM data because of its unique
capability

to

probe

early

aggregation

products
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(oligomers)

and

three-dimensional

characterization of Aβ assembly products relative to other microscopy techniques such as TEM.
48-52

Aggregation of Aβ1-40 proceeds via a nucleation
nucleation-dependent
dependent polymerization mechanism
where a nucleus is first formed before growth by A
Aβ1-40 monomer addition.
ition. This is a raterate
limiting step, and the presence of seeds greatly accelerates aggregation, possibly bypassing the
nucleation step.

Thus it is critical that Aβ1-40 is pretreated to ensure monomeric starting

solutions, using a previously published protocol.53
3.3.2 Assembly of Aβ
β1-40 and with the Various AAMPs
3.3.2.1 Effect of AAMPs on Aβ
β 1-40 ThT Fluorescence

Figure 3.2.. Disruption of fibril formation by designed AAMPs. Time dependent ThT
fluorescence of Aβ1−40 assembly in the presence or absence of the various AAMPs.
Fluorescence (ThT) was set arbitrarily to 100 percent relative to A
Aβ1-40. * denotes mitigators
aged alone.
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Monomeric Aβ1-40 was aged alone and in the presence of equimolar AAMPs (40 µM of Aβ1-40 or
Aβ1-40 /AAMPs) in pH 7.4 phosphate buffer, shaking for 10 min during each h at 37 °C. The
time course of ThT fluorescence for Aβ1-40 aged alone or with equimolar mixture of AAMPs is
presented as a percent of the fluorescence of Aβ1-40 alone (Figure 2). Mitigators aged alone or in
the presence of equimolar Aβ1-40 display time dependent increases in ThT fluorescence,
consistent with increased aggregation although with variable time rates (Figure 2). Results from
ThT fluorescence show minimal fluorescence from mitigators aged alone compared to Aβ1-40 or
AAMP/ Aβ1-40. These results are indicative of very low aggregation to ThT active species. In
some cases, quenching of fluorescent signal was observed after 24 h aging of mitigators alone.
A significant observation was the decrease in total ThT fluorescent signal after 3 months
of incubation in most of the AAMP/Aβ1-40 mixtures. We can speculate that the decreased
fluorescence that is observed results from continuous aggregation of these mixtures that leads to
the formation of larger assemblies, hence precipitating out of solution. In addition, the decrease
also can result from mitigator molecules binding and displacing ThT molecules from mature
fibrils/aggregates. The control peptide (AAMP-0) described by Murphy and coworkers to
enhance Aβ1-40 self-assembly forming a network of fibrils 28 was compared to our designed
mitigators to probe the importance of ααAAs. A mixture of Aβ1-40/AAMP-0 shows an increase
in fluorescence of 120% relative to that of Aβ1-40 alone after 3 days of incubation, and an 80 %
reduction in fluorescence for prolonged aging times. This is consistent with previous reports
describing enhanced Aβ1-40 fibrillogenesis.28, 29
A significant reduction in Aβ1-40 ThT fluorescence is observed when Aβ1-40 is aged with
an equimolar mixture of ααAA-AAMPs. Mitigators AAMP-1, AAMP-2, AAMP-3, AAMP-4,
AAMP-5, AAMP-7, and AAMP-8 exhibit a reduction of ThT fluorescence between 50 and 80%
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relative to that of Aβ1-40 alone, even after 3 months of aging. The only mitigator incorporating
ααAA that displayed a reduced ThT fluorescence of 20% relative to Aβ1-40 was the
dipropylglycine (Dpg)-containing AAMP-6, which remained unchanged for even longer
incubation times (3 months). Comparison of the sequence of AAMP-6 with other AAMPs that
showed reduction in ThT fluorescence between 50-80% relative to the control reveals the
importance of steric effects and position of ααAAs relative to the recognition element.
Therefore, fibrillic assemblies were observed in AAMP-6, which incorporates the less bulky
ααAAs (Dpg) at the C-terminal end of KLVFF recognition core, hence ineffective at blocking
one hydrogen bonding face from addition of extended peptides.
3.3.2.2 Effect of ααAA-AAMPs
on the Secondary Structure of Aβ
β1-40 Using Circular
αα
Dichroism (CD)
To examine the effect of ααAA-AAMPs on Aβ1-40 assemblies, far-UV circular dichroism
(CD) was employed. The CD spectra of unstructured monomeric AAMPs and Aβ1-40 showed a
strong minimum and maximum at around 200 nm and 220 nm respectively, which is consistent
with a random coil conformation. After a week of aging AAMPs alone at 37 °C with shaking,
the random coil conformation observed with monomeric AAMPs remained unchanged with a
minimum and maximum around 200 and 217 nm respectively, however with weaker intensities
(Table 3.1).
Assembly of Aβ1-40 reveals that the time course of forming β-sheet conformation is
consistent with previously reported β-sheet rich assemblies.38, 54 The structure of Aβ1-40 alone
changed from random coil (monomeric) to β-sheet (Figure 3.3) after 7 days of incubation
(maxima at 198 nm and 214 nm). In contrast, an equimolar mixture AAMPs and Aβ1-40 leads to
an unusual CD signature with characteristics of both random coil and β-sheets (Figure 4.3),
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which is consistent with our previous results of AAMP-1/ Aβ1-40 mixture.38 The Maxima and
minima of CD signals for Aβ1-40 aged alone and with the various mitigators aged are presented in
Table 3.1.
Table 3.1. Wavelength and corresponding minimum and maximum ellipticities of CD
analysis of AAMPs alone, Aβ
β1−40 alone and for AAMP/ Aβ
β1−40 mixtures.
entry

AAMPs

1
2

Aβ1−40
AAMP-0

With Aβ (1:1)
3 days aging
λ
Min/Max
(nm) [θ] × 103
206
-4.89
204
-31.34

3

AAMP-2

202

-20.88

218

21.10

4

AAMP-3

202

-50.18

220

-4.12

5

AAMP-4

204

-18.43

221

2.82

6

AAMP-6

202

-50.18

218

-4.41

7

AAMP-7

202

-25.34

222

-5.85

λ
(nm)
220
219

Min/Max
[θ] × 103
-0.275
-1.821

7 days aging
λ
Min/Max
[θ] × 103
(nm)
198
5.03
195
-14.66
(199) (-39.86)
200
-9.89
(199) -36.271
206
0.297
(195) -29.63
203
-7.93
(202) (-22.47)
202
-8.27
(202) (-40.96)
200
-11.20
202
(-22.47)

λ
(nm)
214
207
(221)
218
(217)
220
(213)
213
(215)
219
(219)
224
(221)

Min/Max
[θ] × 103
-14.53
2.4
(3.98)
0.46
15.823
-3.25
(15.22)
-2.95
(11.83)
2.35
(14.12)
-0.69
(13.95)

Note: Values in parenthesis are for AAMPs aged alone after 1 week.

Figure 3.3 Example of CD signature obtained for Aβ1-40 alone, AAMP alone, and Aβ1-40/AAMP
mixture after 1 week aging.
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3.3.2.3 Size and Morphology of the Various Structures as Determined Using AFM
AAMPs aged alone sparsely aggregate forming spherical beads (Figure 3.4) exclusively with
mean height range of 4-10 nm (Table 3.2)
Table 3.2. Mean heights of spherical aggregates observed after 3 days and 1-week aging
the various AAMPs alone.
Entry

Mitigators
3 days
aggregate type

11
12
13
14
15
16
17
18
19

AAMP-0
AAMP-1
AAMP-2
AAMP-3
AAMP-4
AAMP-5
AAMP-6
AAMP-7
AAMP-8

spherical
spherical
spherical
spherical
spherical
spherical
spherical
spherical
spherical

Type/size of nanostructures formed
7 days
90 days
mean height
aggregate type
(nm)
4.9±3.4
amorphous
1.9±1.1
amorphous
2.1±0.9
amorphous
2.2±1.5
amorphous
2.6±3.6
amorphous
4.3±2.3
amorphous
3.5±2.1
amorphous
3.1±1.3
amorphous
3.2±2.3
amorphous

3 days
mean height
(nm)
5.4±2.2
9.6±7.7
5.3±4.3
5.3±3.2
6.3±3.6
6.3±3.6
4.6±3.4
5.1±1.9
4.8±2.5

The absence of fibril formation is consistent with CD results, which show little change in the
random coil conformation with maxima around 220 nm and minima at 217 nm after 1 week of
incubation. Also, the minimal ThT fluorescence observed with AAMPs aged alone relative to
Aβ1-40, suggests that the nanostructures formed are not β-sheet rich. One possible drawback for
the observed spherical beads is that they could act as seeds for Aβ1-40 aggregation, increasing the
rate at which fibrils are formed. However, fibrils were not observed suggesting that particles
produced by AAMPs alone do act as seeds for Aβ fibril formation. We speculate that the
hydrophobic forces are stronger than hydrogen bonding forces resulting in the observed
morphology of aggregates formed. The small-sized spherical aggregates (height ~ 1.6 nm)
formed when AAMP-1 was aged alone for 3 days may explain the toxicity to the cells we have
reported before.55 The various nanostructures formed from aging the various AAMPs alone are
presented in Figure 3.4
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Figure 3.4 Spherical aggregates observed after 1 week aging the various AAMPs alone.
Topographic AFM views of spherical structures formed by:
by:- [A] AAMP-0 [B] Corresponding
height analysis for A; [C] AAMP
AAMP-1 [D] Height analysis for C; [E] AAMP-2;; [F] Height analysis
for E; [G] AAMP-3;; [H] Height distribution histogram for G; [I] AAMP
AAMP-4;; [J] Height analysis
for I; [K]AAMP-5;; [L] Height histogram for K; [M] AAMP-6;; [N] Height analysis for M;
[O]AAMP-7;; [P] Height distribution analysis for O;[
O;[Q]AAMP-8;; [P] Height distribution analysis
for Q;
AFM was used to characterize A
Aβ1-40 or Aβ1-40/AAMP sample aliquots taken at the same
time intervals as those used for ThT fluorescence assay. Images obtained from AFM topography
of aliquots taken at different aging times for A
Aβ1-40, and in presence of AAMP-0, and AAMP-1
are shown in Figure 3.5.. Fibrils were the predominant structures observed after 1 week of aging
Aβ1-40 alone (Figure 3.5A). These fibrils had a mean height of 4.2±2.3 nm which is smaller than
the reported mean height of about 77-10 nm for mature fibrils.47, 56 The mean height is obtained
by taking multiple cursor measurements of the thickness of the fibrils throughout several
representative images and is presented in Table 3.3
3.3.
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Table 3.3. Comparison for nanostructures observed by AFM for Aβ
β1-40 alone and with the
various mitigators.
entry

mitigator

type/size of nanostructures formed
3 days
7 days
90 days
aggregate
mean
aggregate
mean
aggregate
mean
type
height
type
height
type
height
(nm)
(nm)
(nm)
proto/fibril 3.44±2.1
fibrils
4.2±2.3
fibrils
11.1±6.5

1

Aβ1-40

2
3
4
5
6

AAMP-0
AAMP-1
AAMP-2
AAMP-3
AAMP-4

protofibrils
spherical
spherical
spherical
spherical

8.6±5.7
10.7±5.9
5.8±3.6
1.6±1.4
10.2±4.1

fibrils
spherical
spherical
linear
spherical

9.1±3.1
9.6±7.5
8.0±4.4
1.7±1.4
18.1±8.5

7
8

AAMP-5
AAMP-6

3.8±2.8
8.0±5.5

AAMP-7
AAMP-8

spherical
rod like
fibrils
spherical
spherical

5.0±3.5
6.7±2.9

9
10

spherical
protofibril/
linear
spherical
spherical

8.6±4.3
6.2±2.8

12.7±6.8
9.8±5.2

linear
spherical
linear
spherical
rods
spherical
rod like
fibrils
spherical
spherical

9.5±7.0
8.5±3.7
3.7±2.4
43.22
8.0±3.1
8.1±3.2
16.0±8.8
35.9±15.8

The distribution of heights is presented as a histogram for each AFM view. The individual plots
shown for the surface topography of the various samples are representative views of the
morphologies observed for multiple areas of the samples. The presence of smaller sized fibrils is
an indication that protofibrils and some immature fibrils predominate at the early stage, which is
supported by height distribution analysis showing fibrils with diameters 2-4 nm accounting for ≥
60% of total fibrils (Figure 3.5B). In contrast, bundles of fibrils (Figure 3.5C) were observed
after 3 months of incubation as the predominant surface arrangements. The mean height of the
fibrils in the clumps was 11.1±6.5 nm and more than 70% of these fibrils had heights ranging
from 4 to 12 nm (Figure 3.5D) indicating mature fibrils (7-10 nm) had formed.
The assembly of Aβ1-40 into fibrils is consistent with the proposed hierarchical assembly
model (HAM model), which predicts that protofilaments predominate at earlier incubation stages
while protofibrils and fibrils are detected later. The HAM model also predicts that protofibrils
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and fibrils will exhibit periodicity, variations in height, branching, and clumping at various
stages of fibrillization.

The unique arrangement of fibrils on the surface observed after 3

months is consistent with increased β-sheet character of the fibrils.57, 58
The significance of ααAAs in disrupting fibril formation was evaluated by aging
equimolar mixtures of Aβ1-40 with AAMP-0 (no ααAAs) and AAMP-1 (with ααAAs). For
instance, after 3 days of aging AAMP-0/Aβ1-40 mixture, protofibrils (Figure 3.5E) with mean
height of 8.6±5.7 nm were the main structures observed. A dense network of fibrils (Figure
3.5G) with mean height of 9.1±3.1 nm was observed after 1 week of aging. The height analysis
shows a time-dependent increase in fibril heights (Figure 3.5F and 3.5H). In contrast, mixtures
of protofibrils and spherical aggregates (Figure 3I) with a mean height of 9.6±7.5 nm were
observed with AAMP-1 after 1 week of incubation, and rod-like structures (Figure 3.5K) were
formed after 3 months with a slight increase in mean height as displayed in Figures 3.5J and 3.5I.
The peptide AAMP-0 (no ααAAs) was used as a control sample to evaluate the effects of
ααAAs. This peptide (AAMP-0) was shown previously to enhance the rate of aggregation of
Aβ1-40 to form a dense network of fibrils.28 The enhanced Aβ1-40 aggregation rates may also lead
to thicker fibrils as compared to Aβ1-40 fibrils alone. The structural design for AAMP-0 and our
AAMPs are similar except for ααAAs incorporated in the latter (For example Dbg for Phe etc).
The peptide mitigator AAMP-1 was previously communicated to block Aβ1-40 fibrillization even
after 4.5 months of incubation at room temperature.38 The different aggregate morphology
observed from Aβ1-40 aggregation mitigated by AAMP-0 (fibrils) as compared to ααAAcontaining AAMP-1 (mixture of spherical aggregates and rod-like structures) reinforces the
contrast in using ααAA-containing AAMPs to disrupt fibril formation. The results for AAMP-1
with further characterization of the sizes and morphologies of nanostructures formed at different
68

stages of aggregation using high resolution AFM are presented in Figure 3.5I and 3.5K.
Although, AAMP-11 was effective at altering A
Aβ1-40 assembly, for optimal use in vivo and
improved systemicc bioavailability the molecular weight of AAMP
AAMP-1
1 should be reduced as much
as possible. The AAMP-1 analogs were screened for their ability to disrupt Aβ1-40
assembly and
1
were used as a control.

Figure 3.5. Aggregation of Aβ1--40 with and without AAMPs. [A] Fibrils formed by Aβ
A 1-40
alone after 1 week of incubation; [B] Height analysis for A; [C] Fibril bundles formed by Aβ
A 1-40
alone after 3 months of incubation; [D] Height analysis for C; [E] Protofibrils formed after 3
days Aβ1-40 mitigation by AAMP
AAMP-0;
0; [F] Height distribution analysis for E; [G] Fibril network
formed after 1 week Aβ1-40 aggregation mitigation by AAMP
AAMP-0;
0; [H] Height distribution
histogram for G; [I] Mixture of spherical and linear aggregates formed after 1 week Aβ
A 1-40
mitigation by AAMP-1;
1; [J] Height analysis for I [K] Spherical and protofibrils observed after 3
months of Aβ1-40 mitigation by AAMP
AAMP-1; [L] Height distribution histogram for K
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When AAMP-1 analogs with two ααAAs were aged with equimolar Aβ1-40, assemblies
with different heights and morphologies were formed based on the side chain functionality of the
ααAAs used. Spherical aggregates (Figure 3.6A) with mean heights of 8.0 ±4.4 nm and 60% of
the particles with height range of 4-8 nm (Figure 3.6B) were observed after 1 week of aging Aβ140/AAMP-2

mixture. The spherical morphology of the aggregates did not change after 3 months

incubation, but were observed to coalesce forming in some cases aggregate strings (Figure 3.6C).
The only significant change observed was the slight increase in mean heights (8.5±3.7 nm) as
shown by height distribution analysis (Figure 3.6D). Smaller sized spherical aggregates (Figure
3.6E) with mean height 1.7±1.4 nm were formed from coincubation of Aβ1-40 in the presence of
equimolar AAMP-3 as compared to AAMP-2. The same morphology was observed after 3
months incubation (Figure 3.6G), but with a larger mean height (3.7±2.4 nm) as shown by AFM
cursor analysis (Figure 3.6F and 3.6H). Mixtures of spherical aggregates and protofibrils/fibrils
(visible in the background) with mean height of 18.1±8.5 nm (Figure 3.6I) formed after 1 week
of Aβ1-40 mitigation by AAMP-4 as compared to mostly spherical particles observed after 3 days
of incubation. After 3 months of incubation, the mean height of the spherical aggregates (Figure
3.6K) more than doubled (43.2±25 nm) with maximum height spanning to 1 µm as shown in
Figures 3.6J and 3.6L.
The disruption of fibril formation by AAMPs with two ααAAs is an important finding in
that these AAMPs portrayed the same or better disruptive properties as the original AAMP-1
peptide with three ααAAs.

The more interesting aspect of their disruption is the relation

between size and morphology of the particles formed and the side chain functionality of
incorporated ααAAs.

Larger particles with similar morphology were formed from Aβ1-40

aggregation mitigation by AAMP-2 and AAMP-4 as compared to AAMP-3. The difference in
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observed heights could be attributed to the side chain functionality of the ααAAs incorporated in
AAMP-2 (Dbg and Dpg), AAMP-3 (Dibg and Dpg), and AAMP-4 (Dbg and Dibg).
Surprisingly, Dbg (aromatic)-containing AAMPs (AAMP-2 and AAMP-4) formed larger
particles as compared to AAMP-3 without Dbg. Thus incorporation of the additional aromatic
side-chain in Dbg containing AAMPs may play a role in determining the size and morphology of
the resultant nanoparticles because aromatic residues are believed to supply energy, order, and
directionality59,

60

to the Aβ assembly process during fibril formation through aromatic-side

chain stacking interactions.
Hydrophobic or steric effects from ααAAs may also lead to the size and morphology of
structures formed. For instance, larger spherical aggregates with a few protofibrils/fibrils were
formed with AAMP-4 as compared to mainly spherical aggregates for AAMP-2. The different
sizes and morphology of particles formed can thus be related to the combination of the ααAAs
used in each AAMP. They both have aromatic Dbg and a different second ααAAs (Dpg and
Dibg for AAMP-2 and AAMP-4 respectively).

Thus, steric or hydrophobicity differences

between Dpg (n-side chains) and Dibg (branched side chains) has influenced the size and
morphology of the assemblies formed.
Positioning of ααAAs relative to each other in the AAMP sequence could influence the
size and morphology of assemblies formed.

One of the ways to induce extended peptide

conformations required for the interaction with Aβ in short model peptides is to use ααAAs with
larger side-chain groups. For instance, smaller particles were formed by Aβ1-40 mitigation by
AAMP-3 as compared to either AAMP-2 or AAMP-4.

The two ααAAs are in an i, i+2

orientation in AAMP-2 and AAMP-4 as compared to an i, i+4 arrangement in AAMP-3. Other
examples of i, i+2 design mitigators that were designed by replacement of amide backbone
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include n-methyl
methyl groups, ester linkages, and isostructural E
E-olefin
olefin all of which were shown to
mitigate fibril formation.31,

32, 34, 61

Thus placement of the disrupting elements on the same

hydrogen bonding face is crucial for the mitigators to disrupt fibril formation
formatio than their
arrangement. In addition, based on our findings with ααAAs,
AAs, the number of other disrupting
elements reported such as N-methylated
methylated derivatives and ester linkages could be reduced without
affecting their disruptive properties
properties.

Figure 3.6. Disruption of Aβ1-40 fibril formation by AAMPs with two ααAAs; [A] Globular aggregates
formed after 7 days aging Aβ1-40 in presence of AAMP
AAMP-2;
2; [B] Corresponding height distribution analysis;
[C] After 3 months aging; [D] Corresponding height distribution; [E] Spherical aggregates formed after 1
week aging Aβ1-40/AAMP-33 mixture; [F] Height analysis for E; [G] Spherical aggregates after 3 months
aging; [H] Corresponding height analysis; [I] Mixture of spherical aggregates and protofibrils formed
after 7 days aging Aβ1-40 in presence of AAMP
AAMP-4;
4; [J] Corresponding height distribution analysis for I; [K]
After 3 months aging; [L] Matching height distribution histogram.
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The role of AAMPs with only one ααAAs on mitigation of Aβ1-40 aggregation was examined
by aging Aβ1-40 in the presence of equimolar amounts of AAMP-5 (Dibg), AAMP-6 (Dbg), and
AAMP-7 (Dpg). Globular particles were observed to form with AAMP-5 (Figure 3.7A) which
were stable (no fibrils) after 3 months of aging (Figure 3.7C). Height analysis shows that the
percentage of the particles with heights ranging from 4-6 nm increased from ~30% for 1 week of
incubation to over 50% after 3 months of aging (Figure 3.7B and 3.7D). Co-incubation of Aβ140/AAMP-6

mixture produced protofibrillar structures and rod-like fibrils (Figure 3.7E) after 1

week. The protofibrils (Figure 3.7G) observed after 3 months of incubation had increased in
mean height as displayed by height analysis showing a 2-fold increase in the percentage of
particles with heights of 4-6 nm as compared to after 1 week (Figures 3.7F and 3.7H). Aging of
Aβ1-40 with equimolar amounts of AAMP-7 resulted in mainly spherical particles after 3 days.
However, a mixture of spherical aggregates and fibrils/protofibrils (Figure 3.7I) in the
background were detected after 1-week of incubation with over 50% of the particles with heights
ranging from 1-10 nm (Figure 3.7J). After 3 months of aging, the morphology of the particles
(Figure 3.7K) did not change, but their sizes increased as shown by the increase in the percentage
of particles with larger heights (Figure 3.7L). Spherical aggregates (Figure 3.7M) with mean
heights of 9.8 nm were formed from Aβ1-40 mitigation by AAMP-8 after aging for 1 week.
Surprisingly, after 3 months, spherical aggregates (Figure 3.7O) observed earlier have grown in
size to more than a micron in some cases as shown by height analysis (Figure 3.7N and 3.7P)
Results from Aβ1-40 mitigation by AAMPs with one ααAAs further confirms that side
chain functionality of incorporated ααAAs influences the size and morphology of the resulting
nanoparticles. For example, the different morphology of the particles observed in AAMP-5 as
compared to AAMP-6 is because of the steric difference between the ααAAs incorporated.
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Spherical aggregates formed with AAMP-5, which incorporate the more sterically, hindered
Dibg (isobutyl side chains) as compared to rod-like fibrils in AAMP-6, which contains the less
sterically hindered Dpg (n-propyl side chains). In addition, the size and morphology of fibrils
formed by AAMP-6 were different from those of Aβ1-40 alone. Fibrils formed by AAMP-6 had
larger mean heights (6.7 ±2.9 nm) and smaller lengths (≤ 1 micron in length) as compared to
mature Aβ1-40 fibrils, which were smaller in mean height (4.2±2.3nm) and several microns in
length. The short fibril lengths suggest lateral interactions of protofilaments rather than the
intertwining commonly identified during amyloid fibril formation, which can also be because of
a slower growth rate of protofilaments by elongation and dissociation of monomers.

The

branching and polymorphic nature of the fibril lengths observed may have been caused by the
interactions between protofibrils of unequal lengths.58
Positioning of the ααAAs relative to KLVFF core sequence also influences the
morphology of the resulting nanoparticles. The core sequence KLVFF has been shown to be
critical for the inhibitor peptide to interact with Aβ. Thus, mitigators with ααAAs placed
outside this core sequence should have less influence on the interaction with Aβ as compared to
mitigators with ααAAs incorporated into this region. An example is the different morphology of
particles formed from Aβ1-40 mitigation by AAMP-8 (nonfibrillic assemblies) with Dpg
incorporated in the KLVFF core (KLDpgFFAK6) as compared to AAMP-6 (rod-like fibrils) with
Dpg outside the KLVFF core (KLVFFDpgK6. We speculate that the AAMPs with ααAAs
incorporated into the binding motif resulted in increased side-chain to side-chain hydrophobic
interactions with the homologous core of Aβ. Thus, blocking one face from interchain hydrogen
bonding disrupts the Aβ aggregation pathway.
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Figure 3.7 Topographic AFM images showing disruption of A
Aβ1-40 fibril formation by AAMPs
with one ααAAs [A]Views
Views of nonfibrillic assemblies formed after 1 week Aβ
A aggregation
mitigation by AAMP-5;
5; [B] Corresponding height distribution; [C] After 3 months; [D] Height
analysis for C; [E] Progressive AFM Views of rod
rod-like
like fibrils detected after 1 week of aging
ag
Aβ1-40/AAMP-66 mixture; [F] Corresponding height distribution; [G] After 90 days; [H] Height
distribution analysis for G; [I] Views of spherical and protofibrils/fibrils (background) formed by
Aβ1-40/AAMP-77 mixture after 1 week aging; [J] Corresponding height analysis; [K]; After 90
days; [L] Height analysis for K; [M] Views of spherical particles formed by Aβ
A 1-40 aggregation
mitigation by AAMP-8;
8; [N] Corresponding height distribution; [O] After 3 months; [P] Height
analysis for O.
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Interestingly, Aβ1-40 mitigation by AAMP-7 with aromatic Dbg yielded spherical
aggregates after 3 days of aging. However, after 1 week of incubation a mixture of spherical
particles and protofibrils/fibrils in the background with very different morphology relative to Aβ
fibrils were formed. This was an unexpected result since it was predicted to disrupt formation of
fibrillar structures similar to AAMP-5, which incorporates Dibg. A plausible explanation for the
different morphology of particles formed by the two mitigators is the aromatic nature of Dbg
versus Dibg. This could be due to the enhanced aromatic-stacking interactions asserted by the
extra aromatic residue.

In summary, after 3 days of incubation, AAMP-4 and AAMP-7

disrupted fibril formation. However, after 1 week of incubation, a mixture of spherical particles
and protofibrils/fibrils were observed. This indicates that higher ratios of AAMP to Aβ1-40 are
needed to prevent fibril formation.
3.3.2.4 Morphology of Structures Formed from Aβ
β1-40 Aggregation Mitigation by the
Various AAMPs as Observed by TEM
Negatively stained samples of Aβ1-40 alone or mixed with equimolar AAMPs prepared at the
same time as those of AFM and ThT were examined using TEM to confirm the various
morphologies observed with AFM. The morphology of structures (Figure 3.8) formed by Aβ1-40
alone and with the various AAMPs after 1-week aging was consistent with AFM observations.
For instance, Aβ1-40 sample showed a typical appearance of amyloid fibrils, shown as a dense
network of fibrils extending several microns in length. In contrast, Aβ1-40/AAMP mixtures
reveal disruption of Aβ1-40 fibrillization yielding particles with different morphologies.
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Figure 3.8 Morphologies of various particles observed after 11-week aging Aβ
β1-40 in presence
of the various AAMPs. [A] Fibrils formed by A
Aβ1-40 alone; [B] Fibrils formed by Aβ
A 1-40 alone
different view;; [C] Fibrils formed by A
Aβ1-40 alone different view; [D] Fibrils formed from Aβ1-40
mitigation by AAMP-0; [E] Spherical particles formed from aging Aβ1-40 in presence of AAMP1; [F] Spherical particles were observed from aging A
Aβ1-40/AAMP-2
2 mixture;
mixture [G] Spherical
particles formed from Aβ1-40 aggregation mitigation by AAMP
AAMP-3; [H] Mixture of spherical
aggregates and short fibrils weree observed from incubating A
Aβ1-40 in presence of AAMP-4;
AAMP [I]
Spherical particles formed from Aβ1-40 aggregation mitigation by AAMP-5 [J] Fibrils observed
from Aβ1-40 aggregation mitigation by AAMP
AAMP-6 [K] Mixture of spherical and short fibrils formed
from Aβ1-40 mitigation by AAMP
AAMP-7; [L] Spherical particles were observed from aging Aβ
A 1/AAMP-8
mixture
40
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3.3.3 Aβ
β1-40 Fibril Disassembly..
Several laboratories have reported that a dynamic equilibrium exists between Aβ
A 1-40
monomers/dimers and fibrils.36,

62

Thus, a viable strategy to mimic possible dissolution of

plaque
ue deposits commonly present in the brains of patients with AD is to screen for compounds
that can bind to preformed fibrils, shifting the equilibrium towards prefibrillar species. Soto 36, 63
and Meredith 31, 32 have shown that peptides, which incorporate proline ((β-sheet
sheet breaker) and NN
methylated amino acids, have the ability to disassemble mature A
Aβ1-40 fibrils.31, 32, 36 The design
of N-methylated
methylated peptides and our ααAA-containing
containing AAMPs are similar in that both were
designed to block one hydrogen
hydrogen-binding face thus preventing β-sheet
sheet stacking and extension.
Therefore, we hypothesize that ααAA-containing
containing AAMPs should also disassemble preformed
fibrils because of the more bulky side chains
chains, as compared to the methyl group in N-methylated
N
peptides.
3.3.3.1 Thioflavin T Fluorescence.
luorescence.

Figure 3.9.. Disassembly of A
Aβ1-40 preformed fibrils. ThT fluorescence of Aβ
A 1-40 fibril
disassembly by the various AAMPs after 24 h incubation at 37 °C
C while shaking
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To assess the ability of AAMPs to disassemble preformed fibrils, Aβ1-40 was aged for 6
days at 37 °C while shaking. The mature fibrils that formed were mixed with the various AAMPs
at 1:1 molar ratio (40 µM final concentration), and incubated while shaking for 24 h. The extent
of disassembly was measured by ThT fluorescence.

Results of ThT fluorescence for the

disassembly of preformed fibrils by the various AAMPs after 24 h incubation are presented in
Figure 3.9 as %ThT fluorescence relative to that of Aβ1-40 fibrils.
The general reduction in ThT fluorescence for Aβ1-40 fibril/AAMP mixtures relative to
that of Aβ1-40 alone indicates fibril disassembly occurred. For instance, AAMP-1, AAMP-2,
AAMP-3, and AAMP-4 reduced Aβ ThT fluorescence by nearly 80%. This is comparable to the
disassembly of Aβ1-40 fibrils reported for β-sheet breaker peptide (LPFFD),36 RGTFEGKF
peptide,64 and N-methylated peptides,31,

32, 61

although this was at lower AAMP ratios.

Coincidentally, these same mitigators disrupted Aβ1-40 fibril formation by a similar degree.
The other AAMPs (AAMP-0 and Dpg-containing AAMP-6) reduced Aβ1-40 ThT
fluorescence by ~20%. The same mitigators only altered fibril morphology when aged with
monomeric Aβ1-40. It is possible that ThT Fluorescence could give false positive result for fibril
disassembly, because reduction in ThT fluorescence can also result from inhibitor molecules
displacing ThT molecules bound to the preformed fibrils.
3.3.3.2 Size and Morphology of Structures Formed from Disassembly of Preformed Fibrils
by Various AAMPs as Determined Using AFM
Results for disassembly of preformed fibrils by AAMPs are summarized in Table 3.3.
Topographic AFM image of Aβ1-40 taken after six days aging showed a dense network of fibrils
(Figure 3.10A) with a mean height of 6.2 nm. The height analysis (Figure 3.10B) reveals the
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maturity of the fibrils formed, with more than 60% of the fibrils having heights between 4-8 nm,
consistent with the height of mature fibrils (7-10 nm).
Table 3.3. Effect of various AAMPs on Aβ
β1-40 disassembly.
entry Mitigators

 ααAAs

Aggregate type after 24 h
dominant
structures

1

Aβ1-40

-

Fibrils

mean
height
(nm)
6.2±2.6

isolated
structures
-

mean
height
(nm)
-

2
3

AAMP-0
AAMP-1

Dibg, Dbg, Dpg

Fibrils
Spherical

5.4±2.7
5.5±2.9

spherical
fibrils

5.6±2.2
11.2±5.6

4

AAMP-2

Dbg, Dpg

Spherical

3.0±1.2

fibrils

12.4±4.6

5

AAMP-3

Dibg, Dpg

Spherical

7.9±5.0

fibrils

8.4±3.4

6

AAMP-4

Dbg, Dibg

Spherical

11.2±8.2

fibrils

5.2± 2.6

7

AAMP-5

Dibg

Spherical

5.0±4.2

fibrils

5.1±2.1

8

AAMP-6

Dpg

Fibrils

6.6±2.1

spherical

4.7±2.6

9

AAMP-7

Dbg

Spherical

11.3±5.9

fibrillar

5.2±2.5

10

AAMP-8

Dpg

Spherical

10.8±7.5

fibrillar

8.9±4.5

Topographic AFM images of Aβ1-40 fibrils disassembled by AAMP-0 (no ααAAs)
exhibit reduced surface coverage of fibrils and a few spherical particles (Figure 3.10C) consistent
with the 20% reduction in ThT fluorescence observed relative to that of Aβ1-40. Also, this is
consistent with previous reports that AAMP-0 does not induce fibril disassembly. The height
distribution shows a distribution similar to that of Aβ1-40 fibrils (Figure 3.10D). In contrast,
ααAA-containing AAMPs induced disassembly of preformed fibrils to form nonfibrillic
assemblies and isolated protofibrils/fibrils.
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Figure 3.10. Disassembly of A
Aβ1-40 preformed fibrils. [A] Aβ1-40 fibrils; [B] Corresponding
histogram; [C] Fibrils/protofibrils formed as a result of fibril disassembly by AAMP-0;
AAMP
[D]
Height analysis for C; [E] Spherical aggregates induced by AAMP
AAMP-1
1 fibril disassembly; [F]
Height histogram analysis for E; [G] Spherica
Spherical particles formed by AAMP-2
2 fibril disassembly;
[H] Height analysis for G; [I] Spherical aggregates from disassembly by AAMP-3;
AAMP
[J]
Corresponding height analysis; [K] Spherical assemblies formed from fibril disassembly by
AAMP-4;
4; [L] Height histogram for K
Nonfibrillic assemblies and a few isolated fibrillar structures were the main structures
observed from Aβ-40 fibril disassembly by AAMP
AAMP-1 (Figure 3.10E),
E), with three ααAAs. The
same result (nonfibrillic assemblies) was also observed with AAMP
AAMP-2 (Figure 3.10G),
3.10
AAMP-3
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(Figure 3.10I), and AAMP-4 (Figure 3.10K), incorporating two ααAAs as compared to AAMP1. In addition to observing nonfibrillic assemblies, isolated protofibrils (beaded morphology)
and fibrils (smooth) were detected in these mixtures. The height distribution reveals that most of
the particles formed were less than 10 nm in height (Figure 3.10D, 3.10F, 3.10H, 3.10J, and
3.10L). Coincidentally, these same AAMPs showed up to 80% reduction in ThT fluorescence.
Thus, ααAAs play a role in disassembly of preformed fibrils as seen from fibrils being the
predominant species formed with AAMP-0 (no ααAAs) as compared to nonfibrillic assemblies
formed with ααAA-containing AAMPs (for example AAMP-1, AAMP-2 etc). This is consistent
with the ThT fluorescence observations. Significant also, was the increased heights of isolated
fibrils formed by disassembly of preformed fibrils by ααAA-containing AAMPs as compared to
either Aβ1-40 fibrils or AAMP-0 (Table 3.3). This may suggest that ααAAMPs binds to fibrils or
cause the fibrils to coalesce resulting in increased heights.
Disassembly by AAMPs with one ααAA resulted in mixtures of spherical particles and
protofibrils/fibrils. For instance, spherical particles and isolated fibrils/protofibrils were formed
from Aβ1-40 fibril disassembly by AAMP-5 (Figure 3.11A), AAMP-7 (Figure 3.11E) and
AAMP-8 (Figure 3.11G). In contrast, disassembly of performed fibrils by AAMP-6 formed
mainly fibrillar structures (Figure 3.11C) that exhibited a beaded morphology and a periodicity
characteristic of protofibrils.
The spherical particles observed from disassembly by AAMP-7 and AAMP-8 is larger
assemblies as compared to AAMP-5, as shown the height analysis (Figure 8B, 8F, and 8H).
Surprisingly, similar trends were observed for the assembly of Aβ1-40 in the presence of these
AAMPs.

Thus, aromaticity (AAMP-7) and steric effects (AAMP-8) play a part in the

disassembly process. Isolated protofibrils/fibrils observed along with spherical particles for
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AAMP-7 and AAMP-8, were shorter in length and in some with beaded morphology as
compared to Aβ1-40 fibrils. Also, tthe protofibrils/fibrils formed by AAMP-6
6 were shorter and
with beaded morphology but with similar height distribution (Figur
(Figuree 3.11D) and mean height
(Table 3.3) as compared to Aβ
β1-40 fibrils. This suggests that these AAMPs induced partial
disassembly or fibril breakage of preformed fibrils forming protofibrils (beaded morphology)
mo
and short fibrils with mean heights matching those of Aβ1-40 fibrils (Table 3.3).
3.3 The partial
disassembly of Aβ1-40 preformed fibrils and disruption of fibril formation by AAMP-6
AAMP shows
that positioning of ααAAs
AAs relative to KLVFF influences both disassembly and assembly
processes.

Figure 3.11. Disassembly of A
Aβ1-40 preformed fibrils [A] Spherical aggregates induced by
AAMP-55 fibril disassembly; [B] Height histogram analysis for A; [C] Fibrils/protofibrils formed
as a result of fibril disassemblyy by AAMP
AAMP-6;
6; [D] Height analysis for C; [E] Spherical aggregates
from disassembly by AAMP-7;
7; [F] Corresponding height analysis; [G] Spherical assemblies
formed from fibril disassembly by AAMP
AAMP-8; [H] Height histogram for G.
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Figure 3.12 Disassembly of Aβ
β1-40 preformed fibrils. [A] Aβ1-40 preformed fibrils; [B];
[B] Aβ1-40
preformed fibrils zoom in view; [C] Fibrils disassembly by AAMP-0; [D] Mixtures of spherical
aggregates and isolated fibrils
ibrils formed from disassembly by AAMP-1; [E] Isolated short fibrils
formed
rmed from disassembly by AAMP
AAMP-2; [F] Mixtures of spherical aggregates and isolated fibrils
f
formed from disassembly by AAMP
AAMP-3;
3; [G] View of only spherical aggregates formed from
disassembly by AAMP-3; [H] Isolated fibrils formed from disassembly by AAMP-4;
AAMP
[I]
Mixture of spherical
pherical aggregates and fibrils formed from disassembly by AAMP-5;
AAMP
[J] Fibrils
formed from disassembly by AAMP
AAMP-6; [K] Isolated fibrils formed from disassembly by AAMPAAMP
7;; [L] Spherical particles formed by AAMP
AAMP-8.
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The observed disassembly of preformed fibrils into either oligomeric, or prefibrillar
particles (precursors of fibril formation) indicates a shift in equilibrium. It has been shown that
fibrils elongate by monomer addition to the fibril ends.

Therefore, disassembly of fibrils

suggests that AAMP possibly binds at the fibril end which shifts the thermodynamic equilibrium
back towards oligomeric (AAMP-5, AAMP-7 and AAMP-8) and protofibrillar (AAMP-6)
assemblies. Even in cases where fibrils/protofibrils were observed, the surface coverage was
profoundly reduced as compared with the dense network of Aβ1-40 fibrils, suggesting some
amount of disassembly occurred.
3.3.3.3 Morphology of Structures Formed from Disassembly of Preformed Fibrils by
Various AAMPs as Determined Using TEM.
Negatively stained samples of Aβ1-40 pre-formed fibrils or those mixed with various AAMPs
prepared at the same time as those of AFM and ThT were examined using TEM to confirm the
various morphologies observed with AFM. The morphology of Aβ1-40 pre-formed fibrils and
structures resulting from disassembly by the various AAMPs observed after 24 hr aging (Figure
3.12) were consistent with AFM observations. For instance, Aβ1-40 sample showed a typical
appearance of amyloid fibrils, shown as a dense network of fibrils extending several microns in
length. In contrast, Aβ1-40/AAMP mixtures reveal disassembly of Aβ1-40 fibrils yielding particles
with different morphologies.
Our study validates the use of ααAAs as disrupting elements when incorporated into the
KLVFF motif for designing amyloid aggregation mitigating peptides, as indicated by the absence
of fibrillic assemblies in comparison to the control peptide (AAMP-0). We showed that the side
chain interactions associated with the various ααAAs are important in disrupting fibril
formation. A major finding was that the mitigators incorporating one ααAA were as effective in
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disrupting Aβ1-40 fibril formation as the ones with two or three ααAAs. Thus, these findings
support our efforts to reduce the overall molecular weight of the peptide without affecting its
efficacy for optimal in vivo use and improved systemic bioavailability.
Interestingly, we found that the mitigators, which disrupted fibril formation, also
disassembled fibrils.

This suggests the existence of an equilibrium between Aβ1-40

monomers/dimers and fibrils. Molecular dynamic simulations have been employed to study the
mechanism of how these mitigators interact and disassemble fibrils.63, 65, 66 Recently, Yassmine
et al

showed through simulation the disassembly of Aβ16-22 protofibril by N-methylated

inhibitors.67 They reported that N-methylated inhibitors interact with the protofibril by both
lateral and longitudinal association, thereby disrupting the β-sheet extension and its lateral
association into layers. More importantly, they showed that the inhibitor peptides intercalate and
possibly sequester the Aβ peptides, which we believe to be the mode of action for our designed
ααAA-AAMPs in disrupting Aβ1-40 fibrillogenesis. This is also true based on Tycko’s structural
model,68 where we hypothesize that the interaction of ααAA-AAMPs with Aβ1-40 at the region
17-20 disrupts the “bend” segment between the two β-strands, affecting β-sheet extension and
packing during fibril formation.
The formation of oligomeric assemblies, as shown in computer simulations and
experimental data, proceeds via two steps. The initial step is coalescence driven by the rapid
formation of nonspecific hydrophobic interactions. This is followed by a conformational
conversion to ordered β-sheet structures because of the slow formation of highly directional,
interchain hydrogen bonds. Competition between hydrophobic interactions and hydrogen
bonding is important for determining the morphology of aggregates that formed. Aging
conditions can affect hydrogen bonding interactions to yield both fibrillar and non-fibrillar
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assemblies with different morphologies but with the same β-sheet content. Based on our design
strategy, we hypothesized that AAMPs bind Aβ1-40 and block one face of aggregation, which
affects the formation of hydrogen bonding interchains and takes Aβ1-40 fibrillogenesis off the
normal aggregation pathway. This favors hydrophobic interactions over hydrogen bonding and
results in nonfibrillic assemblies.
One possible application of our findings is that ααAAs can be used to control neuronal
toxicity from Aβ species.

Neurotoxicity is believed to be a result of aberrant interactions

between cellular components such as membranes, protasomes and/or molecular chaperons, and
solvent-exposed hydrophobic surfaces of oligomeric assemblies. The size of aggregates affects
these interactions, with the highest toxicity resulting from aggregates with a high surface area to
volume ratio. This explains why fibrils and, to some extent, large oligomers are not very toxic
compared to small oligomeric assemblies. We showed that position, distribution, and side chain
functionality of ααAAs incorporated in the binding core affects the size of the resulting
assemblies. Thus, we can use ααAAs to influence the desired size of aggregates formed, in
hopes of controlling neurotoxicity.69-71 Future cytotoxic experiments will be carried out to
validate this hypothesis.
3.4 Conclusion
Experiments consistently demostrate that mixtures with more than 50% Aβ aggregation
mostly likely contain fibrillic assemblies. This is an important observation because there are
some reports that thioflavin-T binding yields ambiguous results. By compairing our ααAAscontaining mitigators with the control peptide (no ααAAs), we showed the effectiveness of
ααAAs as disrupting elements. Furthermore, we also showed that mitigators with one ααAAs
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were as effective as those with two or three, depending on their position. This is important
because it helps us achieve our goal of reducing the molecular weight of the initial mitigator
AAMP-1 but still maintain/enhance its mitigating properties.
We have demostrated that AAMP-1, AAMP-2, AAMP-3, AAMP-4, AAMP-5, AAMP-7
and AAMP-8, which disrupted fibril formation, also disassembled fibrils forming nonfibrillic
assemblies. We also showed that AAMP-0 and AAMP-5 not only mitigated Aβ1-40 fibril
formation yielding fibrils with a different morphology, but also disassembled preformed fibrils,
forming fibrillar assemblies with similar morphologies to those of protofibrils. This is proof that
there exists an equillibrium between Aβ1-40 monomers/dimers and fibrils.
Mitigators incubated alone slowly aggregated to yield spherical aggregates which may explain
the unexpected toxicity observed with AAMP-1. However, CD spectra showed that after 7 days
of aging the random coil conformation seen for monomers was unchanged. This suggests that
peptides can oligomerize without changes to β-sheet conformation, a property of nearly all
polypeptides. If the AAMPs alone aggregated, they are expected to act as seeds and enhance
abeta aggregation into fibrils. However, AFM and TEM results suggest a different mechanism.
We have shown earlier that AAMP-1 disrupt Aβ1-40 aggregation by acting as co-surfactants.
This has been supported by molecular dynamic simulations using N-methylated amino acids to
intercalate and sesquester Aβ1-40 peptide. There are reports that relate the size of nanoparticles
formed with the maximum toxicity exhibited by particles with high surface area to volume ratios.
Number, side chain fuctionality, and distribution of ααAA nucleates the size and morphology of
Aβ/AAMP products. This is a major finding because ααAAs may be employed as a means to
control the size of resulting nanoparticles and possibly neurotoxicity.
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CHAPTER 4
EFFECTS OF TERMINAL MODIFICATIONS OF PEPTIDES DERIVED FROM Aβ
β
CENTRAL HYDROPHOBIC CORE ON Aβ
β1-40-PEPTIDE AGGREGATE SIZE AND
MORPHOLOGY
4.1 Introduction
A standing hypothesis associated with Alzheimer’s Disease (AD) is that aggregation of
monomeric β-amyloid (Aβ) fibrils into neurotoxic misfolded forms is the key event associated
with the disease pathogenesis.1-3 Recently, extensive investigation of the aggregation pathway
reveals that oligomeric assemblies and not mature fibrils are responsible for Aβ neurotoxicity.4-8
Several approaches have been designed to target the Aβ assembly process in an effort to reduce
toxic species in the brain. Peptide-based approaches in particular, are increasingly becoming a
vital constituent of new therapeutics because of their high specificity and low toxicity as
compared to small organic molecules.9
Several groups have developed amyloid aggregation mitigating peptides (AAMPs) based
on designed changes to the Αβ16-20 central hydrophobic core, KLVFF fragment, which
Tjenberg10, 11 showed to be critical for Aβ self-assembly and self-recognition. To the KLVFF
core, a “disrupter” group is added that solubilizes either inhibitor-Aβ aggregates or blocks
further addition of β-sheets through hydrogen bonding. Disrupters that have been added to
peptides can be classified as N- or C- terminal modifications,12 conformationally constrained
amino acids,13 peptide backbone modifications,14 or the use of D-amino acids.15
An example for N- or C- terminal modifications was the addition of oligolysine chains to
the C-terminus of the KLVFF motif to design peptide KLVFFKKKKKK that was shown to
enhance the rate of Aβ1-40 aggregation into fibrils and thereby prevent toxicity against PC12
cells.12, 16 Also, the rate of Aβ assembly into fibrils was shown to depend on the number of lysine
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groups present in the mitigator. Several modifications of the peptide backbone for the KLVFF
binding motif have been reported. These include replacement of amide hydrogen with methyl
groups,14, 17 and replacement of the amide bond with either an ester bond18 or isostructural Eolefin.19 These modifications were designed to block proliferation of hydrogen bonding between
β-sheets that is necessary for Aβ fibrillization. Peptides derived from these modifications were
found to disrupt Aβ1-40 fibril formation and to disassemble pre-formed fibrils. For instance, Nmethylated peptide Aβ16-22m14 and esterificated Aβ16-20e18 disrupted fibril formation and
caused the disassembly of pre-formed fibrils. Also, it was demonstrated that mutations of the
Phe19-Phe20 amide bond of Aβ1-40 with an E-olefin bond exclusively produced spherical
aggregates and fibrillization was not detected despite incubation periods of up to 6 weeks.19, 20
Conformationally constrained peptides have been shown to be effective at disrupting
Aβ fibril formation through unfavorable steric interactions. For instance, a β-sheet breaker
peptide, iAβ5 containing one proline residue was shown to disrupt fibril formation, disassemble
pre-formed fibrils and protect against neurotoxicity.21 Our approach for this report involves
replacing the hydrogen atom of the α-carbon of natural amino acid residues in the KLVFF motif
with an alkyl substituent. Thus, the conformational freedom of the peptide is restricted and it is
forced to adopt an extended conformation that is ideal for interaction with Aβ1-40. Peptides in an
extended conformation form two faces where one face is available for interaction with Aβ, while
the other is sterically blocked, limiting β-sheet extensions required for amyloid fibril
propagation.
Apart from blocking hydrogen bonding between β-sheets, incorporation of ααAAs
within the KLVFF motif also increases the overall hydrophobicity of the mitigator peptide and in
turn strengthens the hydrophobic interactions with Aβ1-40 target. Polar groups are normally
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added to the highly hydrophobic ααAAs-containing KLVFF core to increase the overall
solubility of the peptide. Also, modification of the α-carbon helps to decrease susceptibility of
the mitigator to proteolytic degradation, which will ensure effective delivery of the inhibitor to
the target organ during in vivo studies. In general, our design for mitigators combines the
advantages of both C-terminal and α-carbon modification.
We have previously developed a mitigator peptide (AMY-1) with C-terminal oligolysine
chain (KDibgVDbgFDpgK6) and a peptide (AMY-2) with an N-terminal oligolysine chain
(K7KDibgVDbgFDpg). Both mitigator peptides AMY-1 and AMY-2 disrupted fibril formation
and formed spherical aggregates of different heights.22 For optimal use in vivo and improved
systemic bioavailability, the charge and molecular weight of the mitigator should be greatly
reduced. Incorporation of one or two ααAAs in the KLVFF binding motif was previously
shown to be as effective at disrupting Aβ1-40 fibrillization as compared to the original peptide
(AAMP-1) with three ααAAs. Herein, effects of forming Aβ fibrils in the presence of (define
acronym) AAMPs incorporating different polar solubilizing groups (C- or N-terminal) are
studied, in an effort to evaluate the effectiveness of reducing the overall charge of the mitigator.
Also, the effects of ααAA-containing AAMPs with fewer polar groups as compared to the
original mitigator AAMP-1 with six Lys are presented.
Peptide analogs modified with α-amino isobutyric acid (also called α-methyl alanine)
have been shown to be more effective at inducing disassembly of Aβ fibrils than either L-proline
or D-amino acids in short model peptides.23, 24 The restrictions imposed by α-methyl alanine or
C-α-tetra substituted-amino acid on conformational freedom are more severe than those of
proline. Thus, mitigators containing bulky substituent’s (ααAAs) could be more effective at
inducing β-sheet disassembly than peptides that incorporate proline. Simulation experiments
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have shown N-methylated peptide Aβ16-22m interacts with Aβ16-22 blocking β-sheet extension,
preventing lateral association into layers and more importantly blocking inhibitor intercalation
for sequestering Aβ peptides. Our ααAAs are bulkier that either N-methylated or α-methyl
alanine model peptide derivatives. Thus, we hypothesize that ααAA-AAMPs could be more
effective at both disrupting fibril formation as well as inducing disassembly of pre-formed fibrils.
4.2 Materials and Methods
All the materials and methodologies used were described in Chapters 2 and 3.
4.3 Results and Discussion
4.3.1 Design of Peptides for Mitigating Aβ Aggregation
Initial work by Tjenberg identified the Aβ central hydrophobic core KLVFF as the key
scaffold for designing disrupters of Aβ1-40  fibrillization.10, 11 Disrupting elements have been
strategically placed at various positions within the Aβ hydrophobic core that either solubilizes
AAMP-Aβ aggregate (Lys or Arg) or blocks one hydrogen boding face inhibiting β-sheet
extension or propagation as with N-Me amino acid or ester bonds. Thus, polar groups such as
Arg, Lys, Glu, and PEG chains were added to increase the solubility of peptides. Certain
mitigators incorporating these polar groups have been shown to be effective at disrupting fibril
formation.16
Surface Plasmon resonance (SPR) was employed by Murphy and coworkers25 to study
the binding of variants related to KLVFF on immobilized Aβ10-35 fibrils.11 Variants with
positively charged residues (KLVFFKn) added to the C-terminus had higher affinities for
immobilized Aβ10-35 fibrils than the KLVFF control, while negatively charged residues
(KLVFFEn) also placed on the C-terminus had a significantly lower binding affinity. In contrast,
N-terminal addition (KnKLVFF) of positively charged residues resulted in lower affinity.
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Binding affinity also is affected by additions of polar groups that do not precede the KLVFF
region in the parent Aβ sequence. Therefore, amino acids (for example Gly) that are
conformationally unrestricted can be used as a “spacer” between the KLVFF motif and
solubilizing residues. Using Gly as a spacer between the mitigator KLVFF core and Arg
residues (solubilizing agents) on both the C- and N- terminus, Brian et al designed the peptide
RGKLVFFGR.26 This peptide was shown to be an effective disrupter of Aβ1-40 fibril formation
and prevent neurotoxicity towards human neuroblastoma SHSY5Y cells.
Table 4.1. Modified AAMPs used to probe the assembly and dissolution of Aβ fibrils.
Entry AAMP

Sequence

1
2

AAMP-11 RGKLVFFGR
AAMP-12 KGKLVFFGK

3

AAMP-13 EGKLVFFGE

4

AAMP-14 (MiniPEG)GKLVFFG(MiniPEG)

5
6
7

AAMP-15 RRRGKLVFFGRRR
AAMP-16 KLVFFGR
AAMP-17 KLVFFG(MiniPEG)

8

AAMP-18 KLVFFGK

9

AAMP-19 RGKLVFF

10

AAMP-20 KLVFFDpgGK

11

AAMP-21 KGKDibgVFFGK

12

AAMP-22 KDibgVFFDpgGKKK

13

AAMP-23 KKKGKLVFFDpgGKKK

14

AAMP-24 KDibgVFFGKKK

15

AAMP-25 KLVFFFDpgGKKK

16

Aβ16-22m

K(Me)LV(Me)FF(Me)AE

*Red color denotes the various polar groups. Blue color denotes ααAAs.
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As part of our continuing work to design more effective ααAA-containing AAMPs, we
employed similar strategies for placing spacers between the AAMP core KLVFF and the
solubilizing groups. We have previously shown that AAMP-1 disrupted Aβ fibril formation.22 In
vivo studies of AAMP-1 on APP transgenic mice displayed elevated toxicity at higher
concentrations.27 The toxicity observed could be related to the six cationic lysine’s which also
affect the delivery of drugs across the hydrophobic brain barrier during in vivo studies. Thus,
positively and negatively charged polar amino acids as well as neutral polar groups such as
MiniPEG was evaluated for effects on the resulting morphology of seed particles and
protofibrils. Our goal was to reduce the overall charge of the original peptide (AAMP-1) without
sacrificing the mitigator ability to disrupt fibril formation and induce disassembly of pre-formed
fibrils.
Peptide mitigator AAMP-11 previously described by Brian and coworkers was used as a
control peptide. First, variants of AAMP-11 were investigated where Arg was replaced with Lys
(AAMP-12), Glu (AAMP-13), and MiniPEG (AAMP-14) to evaluate effects of polar groups on
Aβ1-40 aggregation (Table 1. entries 1-4). Mitigator AAMP-15 allowed us to probe the effect of
increasing the number of Arg in the chain to three on both the C-and N-terminus on
Aβ fibrillogenesis (entry 5). Peptide mitigators (entries 6-8) were designed to evaluate the effect
of placing polar groups only on the C-terminus. The effect of placing polar groups on the Nterminus was evaluated using AAMP-19 with Arg added only to the N-terminus (entry 9). We
have previously shown that three ααAAs incorporated in a mitigator sequence was efficient in
disrupting the process of Αβ fibrillization. Thus, mitigators (entries 10-15) were designed to
probe the effect of the reducing both the number of ααAAs as well polar groups for
Aβ fibrillization. We hypothesize that addition of a spacer between the ααAA containing
100

KLVFF mitigator core and solubilizing residues, would improve the interaction between the
AAMP and the Αβ full sequence length. The N-methylated peptide, Αβ16-22m (entry 16)
previously described to disrupt fibril formation and disassemble pre-formed fibrils was used as a
control peptide because it is similarly designed to block one hydrogen face from β-sheet
extension and packing.
4.3.2 Effects of AAMPs on Aβ
β1-40ThT Fluorescence
Thioflavin T (ThT) undergoes a characteristic spectral change upon binding to fibrillar species,
with maximum emission shifting from 445 to 482 nm.28-30 The intensity of ThT fluorescence is
directly proportional to amyloid fibril formation. However, it has also been shown that
fluorescence can result from ThT dye binding to amorphous aggregates.19, 31 Despite this, ThT
fluorescence is still widely used to monitor the process of Aβ fibrillization. Prior to investigating
the effects of AAMPs on Aβ1-40 aggregation, the individual peptides were first tested alone to
evaluate tendencies to self-aggregate. The individual AAMP solutions were aged in 80 µM in
PBS (pH 7.4) for 1 week at 37 ° with periodic agitation. Under these conditions, all of the
AAMPs exhibited < 10 % reduced fluorescence (Figure 4.1) relative to that of Aβ1-40, which
indicates minimal aggregation into amyloid species.
When Aβ1-40 was aged with the various AAMPs at 1:1 molar ratios (40 µM final
concentration) with periodic agitation, a reduction of Aβ1-40 ThT fluorescence was observed
(Figure 4.2). This suggest a disruption of the assembly process for solutions of Aβ1-40 alone, to
form either nonfibrillic or fibrillar assemblies with different sizes, lengths and morphologies
relative to those of Aβ1-40 alone. The AAMPs with N- and C-termini modified using various
polar groups showed a reduction in ThT fluorescence between 40-70% relative to that of Aβ1-40
after 1-week incubation. In particular, AAMP-11 with polar Arg was the only AAMP with less
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than 50% reduced fluorescence. The similarity in the percentage of reduced ThT fluorescence
fluorescen
indicates that comparable amounts of amyloid were formed. When using ThT alone one, could
falsely argue that AAMP-11
11 is a better disrupter of A
Aβ fibril formation than the other AAMPs
incorporating a polar group on both termini.

Figure 4.1. Time dependent ThT fluorescence assay of A
Aβ alone and AAMPs alone.
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Figure 4.2. Time dependent ThT fluorescence assay of A
Aβ/AAMPs.
The addition of a polar Arg group to only the C-terminus in AAMP-11
11 was found to
exhibit 80% reduced ThT fluorescence. Other AAMPs in the series incorporating MiniPEG
(AAMP-17), Lys (AAMP-18)
18) exhibited a 60% reduction of ThT fluorescence after 1 week of
incubation. This indicates that the morphology or size of aggregates formed by AAMP-16
AAMP
is
different from those formed by either AAMP
AAMP-17 or AAMP-18.
18. Interestingly, mitigators with
polar residues placed on the C-terminus
terminus had an increased reduction in ThT fluorescence as
compared to the corresponding mitigators with polar groups added to both C- and N-termini.
The AAMP-19 with Arg on the N
N-terminus
terminus showed a reduced fluorescence of 40% as compared
to 80% when Arg (AAMP-16)
16) was placed on the C-terminus.
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As part of continuing work for optimizing charge and size of , AAMP-20, AAMP-21,
AAMP-24 and AAMP-25 exhibited reduced fluorescence by less than 40% implying that they
might have comparable amounts of amyloid or similar morphology. However, a potent mitigator
AAMP-22 with two ααAAs and three lysine’s exhibited 80% reduced ThT fluorescence relative
to that of Aβ1-40. Based on ThT results only AAMP-11, AAMP-16, AAMP-22 and AAMP-23
exhibited a higher reduction in ThT fluorescence relative to Aβ than N-methylated peptide,
mAβ16-22 previously reported to disrupt fibril formation and to disassemble pre-formed fibrils.14
As previously described by Austen and coworkers26 AAMP-11 was found to inhibit
oligomer formation and prevent Aβ1-40 toxicity towards neuroblastoma SH-5Y5Y cells. They
reported that an equimolar mixture of Aβ1-40 /AAMP-11 aged for 12 days under quiescent
conditions showed reduced fluorescence of over 80% relative to that of Aβ1-40.26 For the same
peptide after 7 days aging, however we report a lower ThT fluorescence of 63% with a condition
of periodic agitation, as compared to the previously reported result of over 80% reduction.
Agitation is normally employed to enhance Aβ aggregation so that it can be analyzed on a
laboratory time scale, although fibrils formed are less stable and more toxic.32, 33
4.3.3 Effect of Various AAMPs on Aβ1-40 CD Spectra
The effect of ααAA-AAMPs on Aβ1-40 assembly into β-sheet structure, was examined using farUV circular dichroism (CD). The CD spectra of monomeric AAMPs and Aβ1-40 had a strong
minimum near 200 nm and maxima near 220 nm, consistent with an unstructured conformation
commonly referred to as random coil conformation. After 1-week of aging at 37 C while
shaking, all the mitigators exhibited minima in their CD spectra around 200 nm, consistent with
unchanged random coil conformation. However, the assembly of Aβ1-40 alone after 1-week
incubation exhibited a CD spectra with minima around 217 nm (Figure 4.3), consistent with
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formation of β-sheet rich assemblies.22, 34 In contrast, when Aβ1-40 was aged in the presence of
equimolar AAMPs, an unusual CD signature with characteristics of random coil and beta sheet
was observed, consistent with our previous results for an AAMP-1/ Aβ1-40 mixture.22 This
suggests that our AAMPs delay or disrupt Aβ1-40 aggregation into β-sheet rich assemblies.

Figure 4.3. An example of a CD spectra for AAMP-14 alone, Aβ1-40 alone and Aβ1-40/AAMP-14
equimolar mixture.

4.3.4 Assembly of Aβ
β1-40 Alone and with the Various AAMPs Analyzed Using AFM
Samples of AAMPs alone, Aβ1-40 alone, and mixtures of Aβ1-40/AAMPs mixture, which
were prepared for the same time intervals as those of the ThT fluorescence assay were examined
using TEM and AFM. First, samples from mitigator aged alone were examined to determine the
morphology of the aggregates responsible for the observed ThT fluorescence. This is important
because Aβ1-40 has been shown to aggregate via a nucleation dependent polymerization
process.35, 36 Thus, aggregates formed by AAMPs could act as seeds, rapidly increasing the rate
of Aβ assembly into fibrils. Also, AAMP monomer could be added instead to a growing
protofibril in place of Αβ monomer capping the Aβ fibrillization or altering the normal
aggregation pathway leading to formation of fibrils with different morphology. Peptide
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mitigators were aged in the absence of Aβ1-40 PBS (50 mM at 37 C with periodic agitation) to
investigate their self-aggregation. Topographic images of various samples of AAMPs aged for
1-week displayed sparse distribution of aggregates on the surface (Figure 4.4) with mean heights
ranging from 2- 8 nm (Table 4.2).
Table 4.2: Size and morphologies of assemblies obtained from topographic AFM
measurements of products observed from aging AAMPs alone at 37°C.
Entry

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16

AAMPs

AAMP-11
AAMP-12
AAMP-13
AAMP-14
AAMP-15
AAMP-16
AAMP-17
AAMP-18
AAMP-19
AAMP-20
AAMP-21
AAMP-22
AAMP-23
AAMP-24
AAMP-25
Aβ6-22

Type and size of resulting assemblies
3 days
1 week
Aggregate
Size (nm)
Aggregate type
type
spherical
2.5±2.1
spherical
spherical
2.1±1.2
Spherical
spherical
2.7±2.1
Spherical
spherical
2.8±1.7
Spherical
spherical
3.3±1.9
spherical
spherical
2.3±1.5
spherical
spherical
3.1±1.7
spherical
spherical
2.4±1.5
spherical
spherical
2.8±1.8
spherical
spherical
3.1±2.2
spherical
spherical
3.2±2.0
spherical
spherical
2.5±1.6
spherical
spherical
2.3±1.6
spherical
spherical
1.9±1.4
spherical
spherical
2.9±2.5
spherical
spherical
3.9±1.6
spherical

Size (nm)
3.0±2.1
3.1±1.6
5.5±3.4
7.4±4.7
5.3±2.3
2.8±1.8
3.9±2.3
7.9±4.2
3.1±2.1
4.1±2.5
3.6±3.5
4.4±2.3
3.4±2.1
4.4±2.1
3.1±1.9
6.1±3.8

The mean heights of aggregates observed after 1 week of aging shows an increase in height
consistent with aggregation. When the mean heights of aggregates formed by the various
AAMPs were compared, no direct correlation was detected between the mean heights of
aggregates formed and terminal modifications of the peptides. A significant observation was
larger aggregates formed by AAMPs with longer polar groups such as AAMP-14 and AAMP-18
as compared to AAMP-11 or AAMP-12.
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Figure 4.4 Assembly of AAMPs alone at 37°C and periodic agitation. Topographic AFM views
of spherical structures formed by:
by:- [A] AAMP-11
11 [B] Corresponding height analysis for A; [C]
AAMP-12
12 [D] Height analysis for C; [E] AAMP
AAMP-13;
13; [F] Height analysis for E; [G] AAMP-14;
AAMP
[H] Height distribution histogram for G; [I] AAMP
AAMP-15;
15; [J] Height analysis for I; [K]AAMP-16;
[K]AAMP
[L] Height histogram for K; [M] AAMP
AAMP-17;
17; [N] Height analysis for M; [O] AAMP-18;
AAMP
[P]
Height distribution analysis for O;
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Figure 4.5 Assembly of AAMPs alone at 37°C and periodic agitation. Topographic AFM views
of spherical structures formed by:
by:- [A] AAMP-19 [B] Corresponding height analysis for A; [C]
AAMP-20 [D] Height analysis for C; [E] AAMP
AAMP-21;
1; [F] Height analysis for E; [G] AAMP-22;
AAMP
[H] Height distribution histogram for G; [I] AAMP
AAMP-23;; [J] Height analysis for I; [K]AAMP-24;
[K]
[L] Height histogram for K; [M]
M] AAMP
AAMP-25; [N] Height analysis for M; [O] Aβ6-22
6 ; [P] Height
distribution analysis for O;
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Spherical aggregates with mean height range between 3-5 nm were observed for all the
mitigators incorporating ααAAs into its sequence after 1 week of incubation. Surprisingly,
smaller aggregates were observed from topographic images of AAMPs incorporating ααAAs
compared to the more hydrophobic N-methylated control peptide. This suggests that polar
groups present in ααAA-AAMPs play a role in aggregation. When the AAMPs solutions were
aged under quiescent conditions, aggregates were hardly seen indicating that these mitigators are
stable at room temperature.
4.3.4.1 Effect of N- and C-Terminal Modifications of AAMPs on Aβ
β1-40 Fibrillization
The Aβ1-40 sample aged alone showed a dense network of amyloid fibrils averaging 5.4
nm in height and extending several microns in length after 3 days aging (Figure 4.6A). A
predominantly dense network of fibrils averaging 6.9 nm in height and spanning several microns
in length was observed after 1 week of aging (Figure 4.6C). The fibrils that formed are
consistent with the Aβ1-40 aggregation process and fits the proposed hierarchical assembly model
(HAM model).36, 37 The spherical particles observed within a sea of fibrils after 3 days aging are
consistent with results expected with periodic or continuous sample agitation.38 The height
analysis (Figures 4.6B and 4.6D) shows that mature fibrils with diameter ≥7 nm were
predominant after 1 week of aging, which coincides with the results observed with maximum
ThT fluorescence.
When Aβ1-40 was aged with the equimolar ratio of AAMPs incorporating differently
charged polar groups to both C- and N-termini, the normal Aβ1-40 aggregation process was
disrupted to form either fibrils with different morphology (appearance, length) or spherical
particles. A network of protofibrils and fibrils (Figure 4.6E) were the major species observed
after 3 days of aging Aβ1-40 with Arg-containing AAMP-11.
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Table 4.3. Size and morphology of Aβ
β1-40/AAMP variants
Entry

AAMPs

1
2
3
4
5
6

Aβ1-40
AAMP-11
AAMP-12
AAMP-13
AAMP-14
AAMP-15

Type and size of resulting assemblies
3 days
aggregate type
mean
height (nm)
Fibrils
4.5±1.9
Protofibrils/fibrils
4.3±2.0
Protofibrils/ amorphous
5.3±3.1
Amorphous
5.5±3.0
Amorphous
27.8±13.4
Protofibril/linear
4.3±1.9

7
8
9
10
11
12
13
14
15
16
17

AAMP-16
AAMP-17
AAMP-18
AAMP-19
AAMP-20
AAMP-21
AAMP-22
AAMP-23
AAMP-24
AAMP-25
Aβ 6-22

Spherical
Amorphous
Protofibrils/amorphous
Amorphous/protofibrils
Protofibrils
Protofibrils
Spherical
Amorphous/linear
Spherical
Amorphous, protofibrils
Amorphous

20.9±10.1
8.2±3.7
5.5±2.5
5.9±3.3
7.3±3.1
4.8±3.0
5.4±2.3
4.4±2.2
8.7±3.6
5.5±3.4
10.4±4.5

1 week
aggregate type
Fibrils
Protofibrils/fibrils
Rod shaped fibrils
Amorphous
Amorphous
Protofibril/rod like
fibrils
Amorphous
Amorphous
Fibrils
Linear/fibrils
Amorphous/linear
Fibrils
Amorphous
Linear/amorphous
Amorphous, linear
Fibrils
Amorphous

mean
height (nm)
6.9±3.7
6.6±3.1
7.4±3.2
7.2±±
40.1±21.2
5.6±2.2
36.0±15.3
10.0±4.1
7.5±3.2
9.4±3.8
23.9±12
7.6±4.7
6.1±2.8
10±5.1
6.1±2.4
11.5±7.4
16.1±9.5

The morphology of the AAMP-11 structures (Figure 4.6G) observed after 1 week of
aging for the most part did not change, except for an increase was observed for the mean heights
as shown by the histogram analysis (Figures 4.6F and 4.6H). Similarly, fibrils/protofibrils
(Figure 4.6I) were observed after 3 days of aging Aβ1-40 with equimolar AAMP-12 containing
another positively charged group (Lys). After 1 week incubation of AAMP-12 (Figure 4.6K,
there was increase in both the mean height (Figures 4.6J and 4.6L) and surface coverage of
fibrils. Also, when Aβ1-40 was aged with AAMP-13 containing a negatively charged Glu residue,
protofibrils and fibrils (Figure 4.6M) were observed after 3 days. Dense networks of beaded
fibrils or protofibrils (Figure 4.6O) were detected after 1-week incubation with AAMP-13with
height distribution (Figures 4.6N and 4.6P) showing increase in particles size. Interestingly,
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spherical particles (Figure 4.6Q) were the major structures observed after 3 days aging Aβ1-40
with AAMP-14 incorporating a neutral MiniPEG group. No fibrillar species (Figure 4.6S) were
observed after 1-week incubation, only spherical particle clumps were observed resulting in a
height as shown by the height histograms (Figures 4.6R and 4.6T).
Fibrils were observed to form from aging mixtures of Aβ1-40 with AAMP-11 (Figure
4.6E), which is in disagreement with published results where fibrils were not detected.26 The
difference in morphology of the particles that formed could be attributed to differences in the
aging conditions that were employed. Sample agitation is widely used to expedite amyloid fibril
formation. This implies that under quiescent conditions, AAMP-11 disrupts fibril formation;
however, fibril morphology is altered when aggregation rates are increased by agitation. A
mixture of short fibrils with lengths spanning few microns and linear structures with
protofibrillar morphology were observed with AAMP-12 incorporating positively charged Lys.
Both AAMP-11 and AAMP-12 alter Aβ1-40 fibrillization pathway forming fibrils that are short in
length, more branched, and with lower mean height as compared to those of Aβ1-40 fibrils.
Surprisingly, this is consistent with SPR studies that showed mitigators with Lys and Arg polar
residues had identical binding affinities for immobilized Aβ10-35.
However, a dense network of fibrils (Figure 4.6O) with a beaded morphology was
observed when Aβ1-40 was aged with AAMP-13 containing negatively charged Glu, after 1-week
incubation. The dense network of beaded fibrils observed in AAMP-13 as compared to AAMP12 and AAMP-11 is also consistent with lower binding affinity for Aβ from mitigators with
negatively charged polar groups as observed from SPR studies.25
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Figure 4.6. Mitigation of Aβ1-40
40 aggregation by AAMPs with polar groups added to both the Cand N-terminus,
terminus, as viewed by AFM topographs. [A] Fibrils formed after 3 days incubation by
Aβ1-40 alone; [B] Height analysis for A; [C] Fibrils present after 1 week; [D] Height analysis for
C; [E] Fibrils formed after mitigation for 3 days by AAMP
AAMP-11;
11; [F] Height analysis for E; [G]
Fibrils formed after 1 week; [H] Height distribution histogram for G; [I] Mixture of spherical and
protofibril structures after 3 days mitigation by AAMP
AAMP-12; [J] Height
eight analysis for I; [K]
Spherical and short sized fibrils observed after 1 week; [L] Height histogram for K; [M]
Protofibrils present after 3 days with AAMP
AAMP-13;
13; [N] Height analysis for M; [O] Fibrils formed
after 1 week; [P] Height distribution analysis for O; [Q] Spherical structures present after
mitigation for 3 days by AAMP--14;
14; [R] Height distribution for Q; [S] Spherical structures
observed after 1 week; [T] Height analysis for S.
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The lower binding affinities observed from mitigators with negatively charged polar
groups was postulated to be from possible Coulombic interactions between the positively
charged polar groups in the mitigator and negatively charged residues in Aβ (E22 and D23).11 In
contrast, spherical particles with diameters up to nearly 0.2 microns were observed from aging
Aβ1-40 in the presence of AAMP-14 (Figure 4.6Q) with MiniPEG (neutral) group. The MiniPeg
group is a glycol chain and increases the overall hydrophobicity of the peptide. Thus, in this
case increased hydrophobicity is more of a factor as compared to Coulombic interaction
(AAMP-12, AAMP-11) because Aβ assembly is initially controlled by hydrophobic interactions.
4.3.4.2 Effect of C-Terminal Modifications of AAMPs on Aβ
β1-40 Fibrillization
When three Arg residues were added on each terminus as in AAMP-15, fibrils (Figure
4.7A) with lengths up to 1-2 microns were observed in AFM topographs. The fibrils (Figure
4.7C) observed after 1-week incubation had increased height as shown by cursor analysis
(Figures 4.7B and 4.7D). Surprisingly, AAMPs with polar groups added to only the C-terminus
produced particles with a different morphology as compared to those with polar groups added to
both termini. For instance, spherical particles (Figure 4.7E) were the major species observed
from aging Aβ1-40 with AAMP-16 incorporating Arg on the C-terminus. The height of these
particles (Figure 4.7G) increased up to 100 nm after 1-week incubation, shown by height
distributions (Figures 4.7F and 4.7H). Mixtures of protofibrils and spherical particles (Figure
4.7I) were observed after 3 days aging Aβ1-40 in the presence of AAMP-17 containing the neutral
MiniPEG group. After 1 week of aging, spherical and linear particles (Figure 4.7K) with
increased heights (Figures 4.7J and 4.7L) were observed from samples imaged after 1 week.
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Figure 4.7 Disruption of Aβ1-40 fibril formation by AAMPs with polar groups added to the C- or
N-terminus,
terminus, characterized by tapping mode AFM. [A] Views of short fibrils after 3 days aging
Aβ1-40 in the presence of AAMP--15;
15; [B] Corresponding height distribution for A; [C] After 1
week; [D] Height analysis for C; [E] Spherical structures detected after 1 week of aging an Aβ1-40
/AAMP-16
16 mixture; [F] Corresponding height distribution; [G] After 1 week; [H] Height
distribution analysis for G; [I] Views of spherical and protofibrils formed by Aβ1-40
/AAMP-17
1
mixture after 3 days aging; [J] Corresponding height analysis; [K]; After 1 week; [L] Height
analysis for K; [M] Views of spherical particles and protofibrils formed by Aβ1-40
40 aggregation
mitigation by AAMP-18
18 after 3 days aging; [N] Corresponding height distribution; [O] Fibrils
detected after 1 week; [P] Height analysis for O
O.. [Q] Spherical aggregates and protofibrils
observed after 3 days Aβ1-40 mitigation by AAMP
AAMP-19;
19; [R] Height distribution histogram for Q;
[S] Fibrils were present after 1 week aging; [T] Height analysis for S.
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Also, when Aβ1-40 was aged with AAMP-18 containing another positively charged group
(Lys), spherical particles, and protofibrils (Figure 4.7M) were detected for samples imaged after
3 days. Predominantly, fibrils (Figure O) were observed after 1-week incubation of AAMP-18
exhibiting an increased height distribution as compared to spherical/protofibrils observed after 3
days of aging (Figure 4.7N and 4.7P). When Aβ1-40 was aged in the presence of AAMP-19 with
polar groups added to the N-terminus, a mixture of spherical and fibrillar structures (Figure
4.7Q) were observed for AFM images acquired of samples after 3 days aging. Predominantly,
short fibrils spanning few microns (Figure 4.7S) and even distribution (Figures 4.7R and 4.7T)
from those of Aβ were observed from samples taken after 1 week aging.
Contrary to results observed for AAMP-14, increasing the overall hydrophilicity of the
peptide by addition of more positively charged Arg for AAMP-15 did not necessarily lead to
increased disruptive properties. This suggests the importance of the overall hydrophobicity of
the peptide, which has been shown to be involved in the initial process of Aβ assembly.
Modification of the C-terminal of AAMPs with positively charged groups as in AAMP-16 and
AAMP-17 led to disruption of fibrils yielding either non-fibrillar structures or fibrils with
different morphologies (fibril length, fibril diameter, and fibril entanglement) as compared to
structure of Aβ alone. Analogs of KLVF with C-terminal modification with Arg or Lys have
been shown to have significantly larger binding affinities for Aβ.25 Thus, the slight changes
observed for the morphology of the particles could be attributed to the differences in the side
chain functionality of the polar groups, where Arg has a more stable positive charge from
delocalization as compared to Lys.
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Figure 4.8. Disruption of Aβ1-40
containing AAMPs; [A]
40 fibril formation by ααAAs-containing
Protofibrils and spherical structures observed after 3 days aging Aβ1-40 in the presence of
AAMP-20;
20; [B] Height distribution for A; [C] Spherical structures and fibrils (background)
(backg
observed after 1 week; [D] Corresponding height analysis for C; [E] Views of fibrils with some
spherical structures detected after 1 week of aging A
Aβ1-40/AAMP-21
21 mixture; [F] Corresponding
height distribution [G] After 1 week; [H] Height distributio
distribution
n analysis for G; [I] Spherical
structures observed for Aβ1-40 /AAMP
/AAMP-22
22 mixture after 3 days aging; [J] Corresponding height
analysis; [K]; spherical and linear aggregates after 1 week; [L] Height analysis for K.
When the positively charged residue is replaced with a neutral group (MiniPEG), similar
disruption was observed, and could be attributed to enhancing hydrophobic
hydrophobic-hydrophobic
hydrophobic
interactions between Aβ and AAMP
AAMP-17. Mitigators with their N- or C-terminus
terminus modified
modif with
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the same positively charged polar amino acid residue altered Aβ fibrillization forming particles
with different morphology. For instance, fibrils were predominantly formed in AAMP-19 as
compared to spherical particles in AAMP-16 with N- and C-terminal modified with Arg
respectively. This is also consistent with binding studies that showed AAMPs with Lys y added
to the N-terminus had 3-fold lower binding affinities as compared to AAMPs with Lys added to
C-terminus.
4.3.4.3 Effect of N- or C-Terminal Modifications of AAMPs on Aβ
β1-40 Fibrillization
Analogs that incorporate ααAAs were also tested to investigate the effects of ααAAs on
morphology of Aβ -AAMP aggregate. Spherical aggregates and isolated protofibrils (Figure
4.8A) were observed with Dpg-containing AAMP-20 after 3 days of aging. Spherical aggregates
(Figure 4.8C) had grown to ~100 nm in diameter after 1 week of incubation as discerned from
height distribution analysis (Figures 4.8B and 4.8D). Mixtures of spherical aggregates and
fibrils/protofibrils (Figures 4.8E and 4.8G) were observed from aging Dibg-containing AAMP21 after 3 and 7 days incubation. The height distribution of the particles increased over the same
time (Figures 4.8F and 4.8H).
When Aβ1-40 was aged in the presence of AAMP-22 incorporating two ααAAs, spherical
particles (Figure 4.8I) were observed after 3 days while spherical and linear particles (Figure
4.8K) observed after 1 week aging. The diameters and distribution the particles increased at
longer aging times as shown by height analysis (Figures 4.8J and 4.8L). AAMP-20 and AAMP21 are similar in design with AAMP-18 and AAMP-12 except for ααAA incorporated in their
core. Mixtures of spherical aggregates and fibrils were observed with both AAMP-20 and
AAMP-21 with diameters of spherical spanning up to a 0.1 micron as compared to primarily
fibrils, although with different morphology as those of Aβ1-40 .
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Figure 4.9. Effects of ααAAs-containing
containing AAMPs on Aβ1-40 fibril formation; [A] Protofibrils
and spherical structures were observed after 3 days aging A
Aβ1-40 in the presence of AAMP-23;
AAMP
[B] Height distribution for A; [C] Spherical structures and linear structures observed after 1
week; [D] Corresponding height analysis; [E] Spherical structures observed after 1 week of
aging Aβ1-40 /AAMP-24
24 mixture; [F] Height distribution analysis for E; [G] Rod-like
Rod
fibrils and
spherical aggregates observed after 1 week; [H] Corresponding histogram analysis; [I] Spherical
and protofibrillar structures
res observed after aging A
Aβ1-40/AAMP-25
25 for 3 days; [J] Corresponding
height analysis; [K]; After 1 week [L] Height analysis for K.
These are good examples that show the effects of incorporating ααAAs in a mitigator
sequence. When the number of Lys were increased to three and another ααAAs
AAs introduced as in
AAMP-22,
22, compared to AAMP
AAMP-20 with only one Lys and ααAA,
AA, no fibrillar structures were
observed. This is consisted with increased solubility of A
Aβ -AAMP
AAMP aggregate and steric factors ,
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crucial in our mitigator design. This is also consistent with 80% reduced fluorescence observed
relative to that of Aβ1-40.
Spherical and linear structures (Figures 4.9A and 4.9C) were observed in AFM
topographs of samples after three days and 1 week of incubating Aβ1-40 in the presence of
AAMP-23 incorporating Dpg and three lysine residues added to both termini.

Spherical

structures (Figure 4.9E) were observed after 3 days of aging a mixture of Αβ1-40 and AAMP-24.
After 1 week of incubation, spherical aggregates and protofibrils or linear structures (Figure
4.9G) were the predominant structures. On the other hand, after 3 days incubation of an Aβ140/AAMP-25

mixture, spherical aggregates and protofibrils (Figure 4.9I) were observed. After 1

week of aging, fibrils (Figure 4.9K) were more abundant. For all the AAMPs, particles that
formed were observed to increase in height after longer aging ,as shown by height distributions
(Figures 4.9B, 4.9D, 4.9F, 4.9H, 4.9J, and 4.9L).
Addition of three lysine residues to both termini as in AAMP-23, disrupted fibril
assembly to generate linear structures. Addition of three lysines to both ends probably increased
the solubility of Aβ -AAMP aggregates, resulting in disruption of fibrillogenesis. The different
morphologies of the particles observed with AAMP-24 as compared to AAMP-25 can be
attributed to the steric difference between the ααAAs. Mixtures of spherical particles and
protofibrils were formed with AAMP-24, which containing the Dibg (isobutyl side chains) as
compared to fibrils in AAMP-25, which contains Dpg (n-propyl side chains). This highlights the
important role of polar groups and steric hindrance to the mechanisms for disruption of Aβ
fibrillization.
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Figure 4.10 EM micrograph of particles observed after 11-week aging Aβ1-40
40 in presence of the
various AAMPs. [A] Fibrils formed by A
Aβ1-40 alone; [B] Fibrils formed by Aβ1--40 alone different
view; [C]; Zoom in view of A
Aβ1-40 fibrils observed in B [D] Fibrils formed from Aβ1-40
mitigation by AAMP-11; [E] isolated fibrils formed from aging Aβ1-40 in presence of AAMP12; [F] isolated fibrils were observed from aging A
Aβ1-40/AAMP-13 mixture;; [G] mainly spherical
particles and isolated protofibrils observed from aging Aβ1-40 in presence of AAMP-14; [H]
isolated fibrillar structures observed from incubating A
Aβ1-40 in presence of AAMP-15;
AAMP
[I]
Spherical particles formed from Aβ1-40 aggregation mitigation by AAMP-16
16 [J] No fibrillar
particles observed from Aβ1-40
40 aggregation mitigation by AAMP-17 [K] Fibrillar structures
formed from Aβ1-40 mitigation by AAMP
AAMP-18; [L] Fibrils observed from aging Aβ
A 1-40/AAMP-19
mixture.
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4.3.5 Morphology of Structures
tructures F
Formed from Aβ
β1-40 Aggregation Mitigation
itigation by the Various
AAMPs as Observed by TEM

Figure 4.11 EM micrograph of particles observed after 11-week aging Aβ1-40
40 in presence of the
various AAMPs. [A] Isolated fibrils observed from aging A
Aβ1-40/AAMP-20
20 mixture;
mixture [B] nonfibrillar structures formed from aging A
Aβ1-40 in presence of AAMP-21; [C]; non--fibrillar
structures formed from aging Aβ
β1-40 in presence of AAMP-22 [D] Isolated prefibrillar particles
formed from Aβ1-40 mitigation by AAMP
AAMP-23; [E] Mixture of spherical aggregates and isolated
fibrils were formed from aging A
Aβ1-40 in presence of AAMP-24; [F] network of fibrils observed
from aging Aβ1-40/AAMP-25
25 mixture.
Negatively stained samples of A
Aβ1-40 alone or mixed with equimolar
molar AAMPs prepared at
the same time as those of AFM and ThT were examined using TEM to confirm the various
morphologies observed with AFM. The morphology of structures (Figure 3.8) formed by Aβ
A 1-40
alone and with the various AAMPs after 11-week
week aging was consistent with AFM observations.
For instance, Aβ1-40 sample showed a typical appearance of amyloid fibrils, shown as a dense
network of fibrils extending several microns in length. In contrast, A
Aβ1-40/AAMP mixtures
reveal disruption of Aβ1-40 fibrillization yielding particles with different morphologies.
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4.3.6 Aβ
β1-40 Fibril Disassembly
It has been shown that the presence of fibrils in the brain nucleates further deposition of
plaques in AD.39 It was previously stated that a dynamic equilibrium exists between
monomers/dimers and fibrils.21, 40, 41 This makes agents that induce fibril disassembly an
attractive source for development of new therapeutics that will reduce or eliminate plaques in the
brain. Previously, β−sheet
sheet breaker21 and N-methylated peptides14, 40 have been shown to
disassemble pre-formed
formed fibrils. H
Herein,
erein, we designed protocols to evaluate the effect of AAMPs
on Aβ fibril disassembly. Mature fibrils, were formed by incubating A
Aβ1-40 for 1 week at 37 C in
PBS (pH 7.4) while agitating. Equimolar mixtures of fibrils of AAMP/A
AAMP/Aβ1-40 and Aβ
A 1-40 alone
weree aged for 24 h. The extent to which AAMPs induced fibril disassembly was monitored
using ThT fluorescence, as well as images acquired with AFM and TEM. Results of ThT
fluorescence are shown in Figure 4.12 as percentage relative to that of Aβ1-40.

Figure 4.12. Fibril disassembly by various AAMPs as monitored by ThT fluorescence,
presented as percent relative to that of A
Aβ1-40.
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The various AAMPs exhibit reduced fluorescence of more than 50 % relative to that of
Aβ1-40. The N-methylated control peptide Aβ16-22m, which has been shown to disassemble
fibrils, displayed 40 % reduced fluorescence. Based on ThT fluorescence only, the various
AAMPs tested exhibited reduced fluorescence comparable to the N-methylated control peptide.
After 24 h, there is no significant difference in ThT fluorescence observed for AAMPs
incorporating polar groups on the N-and C-terminus (AAMP-11-15), C-terminus (AAMP-1618), N-terminus (AAMP-19) or ααAA-containing AAMPs (AAMP-20-25). It should also be
noted that the reduced fluorescence exhibited by the various AAMPs does not necessarily
indicate the absence of fibrils. This is because inhibitor or disrupter molecules can bind fibrils
displacing bound ThT molecule resulting in reduced fluorescence.
4.3.6.1 Size and Morphology of Structures Formed from Aβ
β1-40 Disassembly by AAMPs
Table 4.4. Effect of various AAMPs on Aβ
β disassembly
entry
AAMPs
size and morphology of resulting assemblies
24 hr
predominant/isolated structures
Size (nm)
1
fibrils
7.9±3.2
Aβ1-40
2
AAMP-11
spherical /protofibrils
6.5±4.3
3
AAMP-12
spherical/fibrils
6.3±3.2
4
AAMP-13
spherical
15.8±10.6
5
AAMP-14
protofibrils/amorphous
19.8±11.1
6
AAMP-15
spherical
7.0±4.0
7
AAMP-16
fibrils/spherical
7.5±4.6
8
AAMP-17
spherical/protofibrils
7.2±3.6
9
AAMP-18
protofibrils/fibrils
11.7±6.7
10
AAMP-19
fibrils
5.3±3.6
11
AAMP-20
protofibrils/fibrils
9.6±4.6
12
AAMP-21
spherical/protofibrils
7.2±3.5
13
AAMP-22
spherical/linear
11.2±6.5
14
AAMP-23
spherical
13.4±8.4
15
AAMP-24
spherical/protofibrils
8.4±3.1
16
AAMP-25
fibrils
8.0±3.8
17
spherical
35.6±20.4
Aβ16-22m
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Figure 4.13. Disassembly of pre
pre-formed fibrils of Aβ1-40. [A] Control sample of Aβ
A 1-40 fibrils.
[B] Corresponding height histogram. [C] Fibrils and spherical structures after disassembly by
AAMP-11;
11; [D] Histogram analysis for C; [E] Partial disassembly by AAMP
AAMP-12;
12; [F] Height
histogram analysis for E; [G] Spherical particles formed by AAMP
AAMP-13
13 fibril disassembly; [H]
Height analysis for G; [I] Spherical aggregates and fibrils(background) formed from
disassembly by AAMP-14;
14; [J] Corresponding height analysis; [K] Isolated fibrils present from
disassembly by AAMP-15;
15; [L] Height histogram for K; [M] Mixture of short and long fibrils
observedd from disassembly by AAMP
AAMP-16;
16; [N] Corresponding height analysis; [O] Fibrils
showing beaded sections for Aβ11-40 fibril disassembly by AAMP-17;
17; [P] Corresponding height
histogram; [Q] Fibrils showing nucleation units for mature fibrils after disassembly by AAMP18; [R] Corresponding height analysis; [S] Partial pre
pre-formed
formed fibril disassembly observed with
AAMP-19;
19; [T] Height histogram for O.
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Parallel AFM experiments were conducted for samples prepared at the same time as
those for ThT fluorescence. A dense network of fibrils with mean height of 7.9 nm was
observed from topographic AFM image of Aβ1-40 sample after 1 week of aging (Figure 4.13A).
Similar observations were found with TEM micrographs, which displayed fibrils spanning
several microns in length. Pre-formed fibrils were mixed with the various AAMPs at 1:1 molar
ratio to evaluate their potential for disassembly. The mean heights and morphologies of the
various structures formed from topographic AFM data are presented in Table 4. 4. Fibrils and
protofibrils were the major structures observed with disassembly of pre-formed fibrils by
AAMP-11 (Figure 4.13C), AAMP-12 (Figure 4.13E), and AAMP-15 (Figure 4.13K) which all
have polar groups added to both the C- and N-terminus.
Spherical aggregates were the main structures observed after disassembly of pre-formed
fibrils by AAMP-13 (Figure 4.13G) and AAMP-14 (Figure 4.13I), which incorporate Glu and
PEG chains respectively into the ,C- and N-terminus. Predominantly, intact fibrils and isolated
spherical particles were the major products observed for disassembly of pre-formed fibrils by
AAMP-16 (Figure 4.13M), AAMP-17 (Figure 4.13O), and AAMP-18 (Figure 4.13Q) with
different polar groups added only to the C-terminus. Partially disassembled fibrils were
observed for AAMP-19 (Figure 4.13S) with polar groups added to N-terminus. Figures 4.13B,
4.13D, 4.13F, 4.13H, 4.13J, 4.13L, 4.13N, 4.13P, 4.13R and 4.13T are the corresponding height
distributions from analysis of multiple cursor profiles.
The surface coverage and morphology (distribution, appearance, length, etc.) of fibrillar
structures formed from disassembly by these mitigators indicates partial disassembly took place.
For instance, fibrillar structures viewed with disassembly by AAMP-15, AAMP-17, and AAMP18, showed nucleation units along the fibril length.
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Figure 4.14. Disassembly of Aβ1-40 pre-formed
formed fibrils imaged using tapping mode AFM. [A]
Fibril disassembly by AAMP-20;
20; [B] Co
Corresponding
rresponding height histogram. [C] Spherical structures
were observed with disassembly by AAMP
AAMP-21; [D] Height analysis for C;; [E] Spherical
structures with disassembly by AAMP
AAMP-22;
22; [F] Corresponding height histogram; [G] Fibrils with
beaded morphology observed
rved from disassembly by AAMP
AAMP-23
23 [H] Height analysis for G; [I]
Spherical aggregates and isolated protofibrils formed from disassembly by AAMP-24;
AAMP
[J] Height
analysis for I;; [K] Fibrils and some spherical species observed from fibril disassembly by
AAMP-25;
5; [L] Corresponding height analysis.
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This is an indication of immature fibrils or protofibrillar structures, which are precursors
of mature fibril formation. In addition, there is evidence of fibril breakage as shown by the
presence of fibrils with lengths less than a micron (AAMP-16) as compared to those of preformed Aβ1-40 fibrils. Spherical particles with diameters up to 0.1 micron were formed in the
presence of AAMP-14. This underscores the importance of overall hydrophobicity and the
length of polar group in the mechanism of disassembly for pre-formed fibrils.
4.3.6.2 Size and Morphology of Structures Formed from Fibril Disassembly by ααAAαα
AAMPs
When ααAA-containing AAMPs were mixed with pre-formed fibrils, the steric nature of ααAAs
played a role in the disassembly process. For instance, fibrils/protofibrils (Figure 4.14A) were
the major species with disassembly by Dpg-containing AAMP-20 as compared to mainly
spherical particles (Figure 4.14C) observed with Dibg containing AAMP-21. Similarly,
spherical particles (Figure 4.14I) and fibrils (Figure 4.14K) were observed for Dibg-containing
AAMP-24 and Dpg-containing AAMP-25. When another ααAAs was introduced to AAMP-24
(Dpg) or AAMP-25 (Dibg) for AAMP-22, spherical particles (Figure 4.14E) with mean height of
11.2 nm were the major structures of disassembly. Addition of three Lys to both termini in Dpgcontaining AAMP-23 (Figure 4.14G) evidenced no fibrils in AFM images, suggesting that
adding polar groups contributes to the disassembly of pre-formed fibrils. Figures 4.14B, 4.14D,
4.14F, 4.14H, 4.14J and 4.14L, provide corresponding analysis of the height distribution of
particles from AFM cursor measurements.
The distribution of ααAAs in the KLVFF motif is a factor in the disassembly of preformed fibrils. For instance, fibrillar structures were the major species formed by AAMPs
incorporating ααAAS outside the KLVFF region as compared to spherical structures observed in
AAMP-20 or AAMP-25 with ααAAs placed in the KLVFF core. Increasing the hydrophobicity
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or steric hindrance by introducing another ααAA as in AAMP-22, induces disassembly of preformed fibrils to form mainly spherical particles. Although not conclusive, greater surface
coverage of disassembled fibrils was observed with AAMP-20 than in the case of AAMP-25
with one and three C-terminal lysines, respectively. Also, AAMP-23 with three lysines were
added to both termini and ααAAs incorporated outside the KLVFF domain, was not expected to
disassemble fibrils; however intact fibrils were not detected, suggesting that added polar groups
also contributes to the disassembly of pre-formed fibrils. This shows that disassembly of preformed fibrils is synergistic combination of the influences of ααAAs as well the number of polar
groups added.
4.3.6.3 Morphology of Structures Formed from Aβ
β1-40 Disassembly by the Various AAMPs
as Observed by TEM
Negatively stained samples of Aβ1-40 pre-formed fibrils or those mixed with various AAMPs
prepared at the same time as those of AFM and ThT were examined using TEM to confirm the
various morphologies observed with AFM. The morphology of Aβ1-40 pre-formed fibrils and
structures resulting from disassembly by the various AAMPs observed after 24 hr aging (Figure
3.12) were consistent with AFM observations. For instance, Aβ1-40 sample showed a typical
appearance of amyloid fibrils, shown as a dense network of fibrils extending several microns in
length. In contrast, Aβ1-40/AAMP mixtures reveal disassembly of Aβ1-40 fibrils yielding particles
with different morphologies.
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Figure 4.15 Disassembly of Aβ
β1-40 preformed fibrils. [A] Aβ1-40 preformed fibrils; [B];
[B] Aβ1-40
preformed fibrils different view; [C] Fibrils disassembly by AAMP-11;; [D] isolated fibrils
formed from disassembly by AAMP
AAMP-12; [E] Fibrils formed from disassembly by AAMP-13;
AAMP
[F]
isolated fibrils formed from disassembly by AAMP
AAMP-14;
14; [G] Non fibrillar structures observed
from disassembly by AAMP-15
15; [H] Fibrils formed from disassembly by AAMP-16;
AAMP
[I] Non
fibrillar structures formed from disassembly by AAMP-17.
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Figure 4.16 Disassembly of Aβ11-40 preformed fibrils. [A] Fibrils observed from disassembly by
AAMP-18; [B];; Fibrillar structures observed from disassembly by AAMP
AAMP-19; [C] Fibrils
disassembly by AAMP-20; [D] Isolated fibrils formed from disassembly by AAMP-21;
AAMP
[E]
Spherical aggregates formed from disassembly by AAMP
AAMP-22; [F] Isolated fibrils
ibrils formed from
disassembly by AAMP-23;
23; [G] Isolated fibrils formed from disassembly by AAMP-24;
AAMP
[H]
Fibrils formed from disassembly by AAMP
AAMP-25; [I] Fibrillar structures from disassembly by
Aβ16-22m;
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4.4 Conclusions
This study demonstrates that terminal modifications of the mitigator core sequence
(KLVFF) with different polar groups altered Aβ fibrillization yielding particles with different
morphologies and sizes. They also disrupt pre-formed fibrils to produce prefibrillar assemblies,
suggesting that an equilibrium exists between fibrils and prefibrillar aggregates. Different results
were obtained with modification of only the C-terminus as compared to changes for both N- and
C- termini. In the process, a mitigator AAMP-16 with the C-terminal modified with Arg was
found to potent disrupter of Aβ1-40 fibril assembly, forming spherical aggregates. This is
consistent with the previously reported use of Arg to solubilize inhibitors of Aβ1-4242 and αsynuclein43 fibrillogenesis, and protects differentiated SHSY-5Y neuroblastoma cells against Aβ
toxicity. Also, AAMPs with a MiniPEG group were found to disrupt Aβ1-40 fibril formation.
This is important because it can be used as a replacement for charged polar groups to improve
systemic bioavailability of a drug during in vivo studies, and hence reduce toxicity as previously
shown for Lys-containing AAMP-1. Smaller-sized spherical particles were observed for
disruption by AAMP-17 as compared to AAMP-14, with C-terminus or C- and N-terminus
modified with MiniPEG, respectively. This indicates that the N-terminal modification enhances
aggregation to form larger assemblies. We have previously reported similar results where large
sizes of particles formed with N-terminal modification of ααAA-KLVFF compared to Cterminal modification using six oligolysine chains.22 The particle size difference is closely
associated with disruption of the hydrophobic C-terminal group44 which has more impact on
aggregation than the hydrophilic N-terminal.45
The different morphologies of particles formed with AAMP-19 (fibrils) and AAMP-16
(spherical aggregates) are attributable of the N-terminal and C-terminal, respectively. Through
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SPR binding studies, Murphy and coworkers have shown that AAMPs with positively charged
polar groups placed on the N-terminus have a 3-fold lower affinity for immobilized Aβ10-35 than
the ones placed on the C-terminus.25 From SPR and our AFM studies, it can be concluded that
mitigators with a higher affinity for the target Aβ1-40 are better disrupters of Aβ fibrillization
Higher binding affinities for AAMPs with polar groups added to the C-terminus as compared to
N-terminus are due to Coulombic interactions between positively charged polar groups in the
AAMP (Lys, Arg) and negatively charged residues (E22 and D23) in Aβ. Coulombic
interactions can also occur for AAMPs with polar groups added to the N-terminus, but the
AAMP has to align in an antiparallel manner to align the two appositively charged groups in Aβ
and AAMP. Even with antiparallel orientation, SPR studies have demonstrated lower binding
affinities as compared to the parallel orientation.25
The AAMPs incorporating ααAAs were better disrupters of Aβ fibrillization as
compared to AAMPs without ααAAs. For instance, linear structures and fibrils were formed
from incubation of Aβ1-40 in the presence of ααAA-containing AAMP-20 and AAMP-18
respectively. This is because incorporating ααAAs in the AAMP core forces the peptide to
adopt an extended conformation that is ideal for interacting with Aβ1-40 through side chain-side
chain hydrophobic interactions. Also, incorporation of ααAAs into the mitigator core increases
its hydrophobic character and in essence, impacts Aβ1-40 assembly since the initial aggregation is
controlled by hydrophobic interactions. Mitigator AAMP-22 incorporating two ααAAs in the
KLVFF motif and containing three lysines on the C-terminus was found to have similar
disruptive properties as compared to AAMP-3 (Chapter 3) with six lysines.22 This shows that the
number of lysines can be reduced without affecting solubility and disruptive properties of the
mitigator.
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Topographic AFM data of the disassembly of pre-formed fibrils show agreement with
data from ThT fluorescence. The lower percent ThT fluorescence exhibited by AAMP/ Aβ1-40
mixtures is consistent with the observations of lower surface coverage of fibrils. Peptides, which
have their termini modified with Lys, Arg, Glu and glycol chains have been shown to be
effective at disrupting fibril formation as well as to protect against neuronal toxicity.14, 18, 26, 46
Fibrils/protofibrils were observed in AAMPs without ααAAs as with AFM and TEM data.
Mitigators, AAMP-21, AAMP-22, AAMP-23 induced disassembly of pre-formed fibrils to a
similar degree to N-methylated peptide, Aβ16-22m which was previously shown to disassemble
pre-formed fibrils.14 The N-methylated, Aβ16-22m as disassembled pre-formed fibrils, yielded
large spherical aggregates with mean heights of 35.6 nm. In contrast, smaller aggregates were
observed with ααAA-AAMPs. The difference in the height of assemblies that formed can only
be attributable to the added polar groups. Thus, polar groups play a role in determining the size
of assemblies formed. We hypothesize that substitution of hydrogen atom on α-carbon of certain
amino acids in the critical KLVFF region with an alkyl substituent yields a more hydrophobic
peptide. Initial assembly of Aβ oligomers is controlled by the hydrophobic side-chains. Thus,
increasing the hydrophobicity of this region should also enhance interactions between Aβ and
the mitigator, leading to both disruption of Aβ assembly into fibrils as well as the disassembly of
pre-formed fibrils.
Also, because of terminal modifications with different polar groups, potent mitigators of
Aβ1-40 fibrillization were found, where the most interesting are the ones with neutral MiniPEG
polar groups. Previous designs mostly used positively charged amino acids such as Lys or Arg,
which makes peptide delivery through the brain barrier difficult. Thus, this study serves as a
foundation for future design of more effective peptides with increased systemic bioavailability
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and for optimal use in vivo. In addition, there is increasing evidence that an equilibrium exists
between fibrils and monomers.41, 47, 48 Mitigator KLVFFK6 was previously shown by Murphy
and coworkers to alter the Aβ1-40 fibrillization process, forming fibrils with different
morphologies that were protective against Aβ cytotoxicity. The non-toxic nature of these fibrils
is believed to be because they are stable to the equilibrium change unlike Aβ fibrils which are in
constant equilibrium with the more toxic oligomeric assemblies.12 Thus, future cytotoxicity
experiments on mitigators that form fibrils with different morphology as those of Aβ1-40 fibrils
will further provide a basis for design of mitigators that result in fibrils that are stable and protect
against neurotoxicity. Also, we designed mitigators that induced partial disassembly of preformed fibrils. The mechanism of disassembly is believed to occur by mitigator monomers
binding to the end of fibrils and shifting equilibrium towards prefibrillar assemblies. Thus, this
study can guide future designs of dissolution agents. Lastly, it is possible now to introduce
unnatural amino acids into a given protein selectively in a cell; therefore, ααAAs would be
valuable for studying the structural elements responsible for Aβ toxicity in animal models of
AD.
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CHAPTER 5
SUMMARY
5.1 Discussion
This dissertation focused on design and synthesis of short model peptides that incorporate
ααAAs in the core sequence. ααAAs are known to induce extended peptide conformation (two
hydrogen bonding face) in a model peptide such that one face is blocked by ααAAs and the
other is available for interaction with Aβ via side-chain, side-chain hydrophobic interactions.1, 2
Thus, a series of ααAA-containing AAMPs were designed.
Chapter 2 of this dissertation describes the synthesis of ααAAs and incorporation into a
short model peptides.

Dipropylglycine (Dpg) and Diisobutylglyicine (Dibg) were easily

synthesized following Fu protocols.3-5 Procedural adjustments especially in the reaction workup
resulted in increased yields. Dpg was also synthesized in high yields via palladium catalyzed
alkylation reaction. Dibenzylglycine (Dbg) was difficult to synthesize in large amounts such that
it was enough for peptide synthesis. The was because the dialkylated ester was unstable to rotary
evaporation and distilled out with the solvent into the waste flask. With the increasing success of
microwave irradiation to hydrolyze sterically hindered hydatoins,6,

7

I hypothesize that Dbg

hydantoin too can be successfully hydrolyzed using microwave irradiation such that it can easily
be synthesize in high yields using Bucherer-Bergs method,8 the most common way of
synthesizing ααAAs. Acylation of N-terminus of ααAAs during peptide synthesis was found to
be difficult as shown by the very low coupling yields. Coupling yields were also improved using
microwave irradiation and a library of AAMPs designed was successfully synthesized.
Chapter 3 describes solution analysis of the various AAMPs for their ability to disrupt
properties against Aβ fibrillization. AAMP-1, which has three ααAAs incorporated in the core
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sequence, was shown previously to disrupt Aβ fibril formation yielding non-fibrillic assemblies
that were still stable after 4.5 months.9 In this Chapter, the role of individual ααAAs was
investigated for their effects on the resulting Aβ-AAMP aggregate size and morphology. The
number and position of ααAAs relative to the KLVFF core was shown to be crucial for the
AAMP to disrupt Aβ fibrillization. Also, for the first time ααAA-containing AAMPs were
found to induce fibril disassembly. These ααAA-AAMPs disassemble fibrils by binding to Aβ
fibril and because of their bulky side chains, it hinders both β-sheet extension and lateral
association into layers10
Chapter 4 describes terminal modifications of AAMPs derived from Aβ central
hydrophobic core with differently charged polar residues. Terminal modifications of peptides
derived from Aβ central hydrophobic core have been shown previously to affect the Aβ-AAMP
binding affinity or aggregate size and morphology. For instance Murphy and Coworkers
showed that polar groups added to C-terminus have more affinity for immobilized Aβ10-35 than
polar groups added to the N-terminus.11 Also, Fu et al showed that AMY-2 with six lysines
added to N-terminus aggregated faster forming large assemblies as compared to AMY-1 with six
lysine’s added to C-terminus.12,

13

Thus, in this chapter terminal modifications using polar

residues with different charged led to several potent mitigators of Aβ assembly, majority of
which incorporate polar groups to the C-terminus. More importantly, AAMPs incorporating
miniPEG polar groups were found to be effective against Aβ fibrillization. It is imperative to
design mitigators that can easily be delivered through the brain barrier to their targets. Thus,
future design of mitigators should include uncharged polar groups such as miniPEG. Also, the
number of both Lys and ααAAs was reduced without changing the ability of the AAMP to
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disrupt fibril formation. This is important because our original goal of reducing the charge and
size of the AAMP was achieved.12, 13
Currently collaborative work with Dr. Keller at LSU Pennington is ongoing to test the
assemblies formed from Aβ mitigation by these AAMPs on primary neurons.
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